Medicure (MCUJF) 20-F 30 Apr 19 2018 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2018shares
Document And Entity Information [Abstract]
Entity Registrant Name	MEDICURE INC
Entity Central Index Key	0001133519
Trading Symbol	mph
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding	15,547,812
Document Type	20-F
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	false
Entity Shell Company	false

Consolidated Statements of Fina

Consolidated Statements of Financial Position - CAD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 24,139,281	$ 5,260,480
Short-term investments	47,747,000
Accounts receivable (Note 6)	10,764,579	8,588,255
Consideration receivable (Note 5)		82,678,366
Inventories (Note 7)	4,239,267	3,075,006
Prepaid expenses	2,696,693	903,914
Assets held for sale (Note 5)		14,052,861
Total current assets	89,586,820	114,558,882
Non-current assets:
Property, plant and equipment (Note 8)	316,013	221,622
Intangible assets (Note 9)	1,705,250	1,756,300
Holdback receivable (Note 5&10)	11,909,368	12,068,773
Other assets	116,786
Deferred tax assets (Note 13)	127,176	326,108
Total non-current assets	14,174,593	14,372,803
Total assets	103,761,413	128,931,685
Current liabilities:
Accounts payable and accrued liabilities (Note 9, 15(a), 16(a) & 16(b))	14,378,215	10,371,103
Accrued transaction costs (Note 5)		22,360,730
Current income taxes payable (Note 13)	1,058,487	2,428,560
Current portion of royalty obligation (Note 11)	1,495,548	1,537,202
Liabilities held for sale (Note 5)		6,976,313
Total current liabilities	16,932,250	43,673,908
Non-current liabilities
Royalty obligation (Note 11)	2,035,010	2,911,810
License fee payable (Note 9)		501,800
Other long-term liabilities	1,200,608	1,135,007
Total non-current liabilities	3,235,618	4,548,617
Total liabilities	20,167,868	48,222,525
Equity:
Share capital (Note 12 (b))	122,887,105	125,733,727
Warrants (Note 12(d))	1,948,805	1,948,805
Contributed surplus	7,628,188	6,897,266
Accumulated other comprehensive income	1,267,717	673,264
Deficit	(50,138,270)	(54,543,902)
Total Equity	83,593,545	80,709,160
Total liabilities and equity	103,761,413	128,931,685
Commitments and contingencies (Note 15(a) & 15(d))
Subsequent events (Note 10, 12(b), 15(a) & 21)	$ 0	$ 0

Consolidated Statements of Net

Consolidated Statements of Net Income and Comprehensive Income - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue, net
Product sales, net	$ 29,109,365	$ 27,132,832	$ 29,304,800
Cost of goods sold (Note 7 & 9)	4,152,238	3,464,686	3,721,191
Gross profit	24,957,127	23,668,146	25,583,609
Expenses
Selling, general and administrative	19,502,337	14,867,635	15,417,604
Research and development	6,681,013	5,148,233	3,630,079
Other expense	26,183,350	20,015,868	19,047,683
(Loss) income before the undernoted	(1,226,223)	3,652,278	6,535,926
Other expense (income):
Revaluation of holdback receivable (Note 10)	1,472,999	(82,489)
Impairment loss (Note 9)		635,721
Total Other (income) expense	1,472,999	553,232
Finance (income) costs:
Finance (income) expense, net (Note 14)	(1,060,932)	837,461	2,478,914
Foreign exchange (gain) loss, net	(6,460,805)	(175,459)	262,469
Total Finance costs (income)	(7,521,737)	662,002	2,741,383
Net income before income taxes	4,822,515	2,437,044	3,794,543
Income tax (expense) recovery
Current (Note 13)	(677,900)	9,392,836	(501,315)
Deferred (Note 13)	(218,976)	(333,187)	331,095
Income tax expense	(896,876)	9,059,649	(170,220)
Net income before discontinued operations	3,925,639	11,496,693	3,624,323
Net income from discontinued operations, net of tax (Note 5)	0	31,924,191	23,358,318
Net income	3,925,639	43,420,884	26,982,641
Translation adjustment, attributable to:
Continuing operations	594,453	(30,295)	(400,829)
Discontinued operations		21,567	(21,567)
Comprehensive income	$ 4,520,092	$ 43,412,156	$ 26,560,245
Earnings per share from continuing operations
Basic (Note 12(e))	$ 0.25	$ 0.74	$ 0.24
Diluted (Note 12(e))	0.24	0.63	0.21
Earnings per share from discontinued operations
Basic (Note 12(e))	0	2.04	1.56
Diluted (Note 12(e))	0	1.76	1.35
Earnings per share
Basic (Note 12(e))	0.25	2.78	1.80
Diluted (Note 12(e))	$ 0.24	$ 2.39	$ 1.56

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - CAD ($)	Share Capital	Warrants	Contributed Surplus	Accumulated other comprehensive income (loss)	Deficit	Total	Non-Controlling Interest	Total
Balance at Dec. 31, 2015	$ 121,413,777	$ 101,618	$ 6,789,195	$ 1,104,388	$ (124,947,427)	$ 4,461,551		$ 4,461,551
Net income for the year ended					26,982,641	26,982,641		26,982,641
Other comprehensive (loss) income for the year ended				(422,396)		(422,396)		(422,396)
Acquisition of non-controlling interests							$ 2,090,000	2,090,000
Transactions with owners, recorded directly in equity
Issuance of warrants (Note 12(d))		1,948,805				1,948,805		1,948,805
Stock options exercised (Note 12(c))	3,217,125		(1,372,995)			1,844,130		1,844,130
Warrants exercised (Note 12 (d))	69,443	(30,271)				39,172		39,172
Share-based compensation (Note 12(c))			1,340,001			1,340,001		1,340,001
Total transactions with owners	3,286,568	1,918,534	(32,994)			5,172,108		5,172,108
Balance at Dec. 31, 2016	124,700,345	2,020,152	6,756,201	681,992	(97,964,786)	36,193,904	2,090,000	38,283,904
Net income for the year ended					43,420,884	43,420,884		43,420,884
Other comprehensive (loss) income for the year ended				(8,728)		(8,728)		(8,728)
Disposition of non-controlling interests							$ (2,090,000)	(2,090,000)
Transactions with owners, recorded directly in equity
Stock options exercised (Note 12(c))	869,703		(349,704)			519,999		519,999
Warrants exercised (Note 12 (d))	163,679	(71,347)				92,332		92,332
Share-based compensation (Note 12(c))			490,769			490,769		490,769
Total transactions with owners	1,033,382	(71,347)	141,065			1,103,100		1,103,100
Balance at Dec. 31, 2017	125,733,727	1,948,805	6,897,266	673,264	(54,543,902)	80,709,160		80,709,160
Net income for the year ended					3,925,639	3,925,639		3,925,639
Other comprehensive (loss) income for the year ended				594,453		594,453		594,453
Transactions with owners, recorded directly in equity
Buy-back of common shares 1	(3,501,333)				479,993	(3,021,340)		(3,021,340)
Stock options exercised (Note 12(c))	654,711		(291,253)			363,458		363,458
Share-based compensation (Note 12(c))			1,022,175			1,022,175		1,022,175
Total transactions with owners	(2,846,622)		730,922		479,993	(1,635,707)		(1,635,707)
Balance at Dec. 31, 2018	$ 122,887,105	$ 1,948,805	$ 7,628,188	$ 1,267,717	$ (50,138,270)	$ 83,593,545		$ 83,593,545

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash (used in) provided by: Operating activities:
Net income from continuing operations for the year	$ 3,925,639	$ 11,496,693	$ 3,624,323
Net income from discontinued operations for the year (Note 5)	0	31,924,191	23,358,318
Net income	3,925,639	43,420,884	26,982,641
Adjustments for:
Gain on sale of Apicore (Note 5)		(55,254,236)
Current income tax expense (recovery) (Note 13)	677,900	(9,392,836)	504,586
Deferred income tax expense (recovery) (Note 13)	218,976	(1,513,868)	301,512
Impairment loss (Note 9)		635,721
Revaluation of holdback receivable (Note 10)	1,472,999	(82,489)
Revaluation of long-term derivative			(20,560,440)
Gain on step acquisition			(4,895,573)
Amortization of property, plant and equipment (Note 8)	103,207	1,173,019	189,008
Amortization of intangible assets (Note 9)	195,977	6,633,957	2,192,024
Share-based compensation (Note 12(c))	1,022,175	623,115	1,400,241
Write-down (write-up) of inventories (Note 7)	94,517	385,289	(108,817)
Finance (income) expense, net	(1,060,932)	837,461	3,416,678
Unrealized foreign exchange (gain) loss	(5,322,916)	270,663	215,386
Change in the following:
Accounts receivable	(1,340,746)	(3,713,375)	(4,174,691)
Inventories	(1,258,778)	145,339	2,520,499
Prepaid expenses	(1,792,779)	76,724	1,706,109
Other assets		33,130	(1,229)
Accounts payable and accrued liabilities	7,131,998	48,398,200	143,257
Deferred revenue		(621,455)	(382,727)
Other long-term liabilities		77,467	(102,828)
Interest received (paid), net (Note 14)	255,119	(7,485,956)	(1,223,664)
Income taxes paid	(2,041,317)	(894,327)
Royalties paid (Note 11)	(1,538,766)	(1,829,295)	(1,712,390)
Cash flows from operating activities	742,273	21,923,132	6,409,582
Investing activities:
Proceeds from Apicore Sale Transaction (Note 5)	65,234,555	89,719,599
Purchase of short-term investments	(44,100,000)
Acquisition of Class C common shares of Apicore		(31,606,865)
Acquisition of Class E common shares of Apicore		(2,640,725)
Acquisition of Apicore, net of cash acquired			(41,711,546)
Acquisition of property, plant and equipment (Note 8)	(197,494)	(1,194,703)	(464,208)
Acquisition of intangible assets (Note 9)	(1,280,540)	(127,144)
Cash flows from (used in) investing activities	19,656,521	54,150,162	(42,175,754)
Financing activities:
Repurchase of common shares under normal course issuer bid	(3,021,340)
Proceeds from exercise of stock options (Note 12 (c))	363,458	519,999	1,844,130
Proceeds from exercise of Apicore stock options (Note 12 (c))		421,942
Proceeds from exercise of warrants (Note 12 (d))		92,332	39,172
Issuance of long-term debt			56,781,184
Repayment of long-term debt		(75,180,908)	(1,666,666)
Repayment of note payable to Apicore (Note 5)		(18,507,400)
Increase in short-term borrowings		161,923	332,555
Decrease (increase) in cash held in escrow		12,809,072	(12,809,072)
Finance lease payments		(101,946)	(10,463)
Payment of due to vendor (Note 4)		(3,185,945)
Cash flows (used in) from financing activities	(2,657,882)	(82,970,931)	44,510,840
Foreign exchange (loss) gain on cash held in foreign currency	1,137,889	(108,060)	(47,083)
Increase (decrease) in cash	18,878,801	(7,005,697)	8,697,585
Cash and cash equivalents, beginning of period	5,260,480	12,266,177	3,568,592
Cash and cash equivalents, end of period	$ 24,139,281	$ 5,260,480	$ 12,266,177

Reporting entity

Reporting entity	12 Months Ended
	Dec. 31, 2018
Nature Of Reporting Entity [Abstract]
Reporting entity	1. Reporting entity Medicure Inc. (the "Company") is a company domiciled and incorporated in Canada and as of October 24, 2011, its Common Shares are listed on the TSX Venture Exchange (“TSX-V”). Prior to October 24, 2011 and beginning on March 29, 2010, the Company's Common Shares were listed on the NEX board of the TSX-V. Prior to March 29, 2010, the Company's Common Shares were listed on the Toronto Stock Exchange. Additionally, the Company's shares were listed on the American Stock Exchange (later called NYSE Amex and now called NYSE MKT) on February 17, 2004 and the shares ceased trading on the NYSE Amex effective July 3, 2008. The Company remains a U.S. Securities and Exchange Commission registrant. The address of the Company's registered office is 2-1250 Waverley Street, Winnipeg, Manitoba, Canada, R3T 6C6. The Company is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics. Through its subsidiary Medicure International, Inc., the Company has rights to the commercial product AGGRASTAT ® ® On December 14, 2017, the Company announced, through its subsidiary Medicure International, Inc., it had acquired an exclusive license to sell and market a branded cardiovascular drug, TM TM in the United States. On May 1, 2018 the Company announced the commercial availability of ZYPITAMAG TM The Company’s ongoing research and development activities include the continued development and further implementation of a new regulatory, brand and life cycle management strategy for AGGRASTAT ® During 2017, the Company, through Apicore, was involved in the manufacturing, development, marketing, and selling of Active Pharmaceutical Ingredients

Basis of preparation of financi

Basis of preparation of financial statements	12 Months Ended
	Dec. 31, 2018
Disclosure Of Basis Of Preparation Of Financial Statements Explanatory [Abstract]
Basis of preparation of financial statements	2. Basis of preparation of financial statements (a) Statement of compliance These consolidated financial statements of the Company and its subsidiaries were prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). The consolidated financial statements were authorized for issue by the Board of Directors on April 10, 2019. (b) Basis of presentation The consolidated financial statements have been prepared on the historical cost basis except for the following items: · Derivative financial instruments are measured at fair value. · Financial instruments at fair value through profit or loss (“FVTPL”) are measured at fair value. · Assets and liabilities of Apicore’s Indian business which are held for sale at December 31, 2017 are recorded at fair value. (c) Functional and presentation currency The consolidated financial statements are presented in Canadian dollars, which is the Company's functional currency. All financial information presented has been rounded to the nearest dollar except where indicated otherwise. (d) Use of estimates and judgments The preparation of these consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenue and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Areas where management has made critical judgments in the process of applying accounting policies and that have the most significant effect on the amounts recognized in the consolidated financial statements include the determination of the Company’s and its subsidiaries’ functional currencies. Information about key assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amount of assets and liabilities within the next financial year are included in the following notes to the consolidated financial statements for the year ended December 31, 2018: · Note 3(c)(i): The valuation of the holdback receivable · Note 3(c)(ii): The valuation of the royalty obligation · Note 3(e): The provisions for returns, chargebacks, rebates and discounts · Note 3(k): The measurement of intangible assets · Note 3(q): The measurement of the amount and assessment of the recoverability of income tax assets and income tax provisions

Significant accounting policies

Significant accounting policies	12 Months Ended
	Dec. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Significant accounting policies	3. Significant accounting policies The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements, unless otherwise indicated. (a) Basis of consolidation These consolidated financial statements include the accounts of the Company and its subsidiaries. Subsidiaries are entities controlled by the Company. Control exists when the Company has power over the investee and when the Company is exposed, or has the rights, to variable returns from the investee. Subsidiaries are included in the consolidated financial results of the Company from the effective date of acquisition up to the effective date of disposition or loss of control and include wholly owned subsidiaries, Medicure International Inc., Medicure Pharma Inc., Medicure U.S.A. Inc., Medicure Mauritius Limited, Medicure Pharma Europe Limited and Apigen Investments Limited. Additionally, the December 31, 2016 comparative figures include, (b) Foreign currency Items included in the financial statements of each of the Company's consolidated subsidiaries are measured using the currency of the primary economic environment in which the subsidiary operates (the functional currency). The consolidated financial statements are presented in Canadian dollars, which is the Company's functional and presentation currency. Foreign currency transactions are translated into the respective functional currencies of the Company and its subsidiaries using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Non-monetary items that are not carried at fair value are translated using the exchange rates as at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. The results and financial position of the Company's foreign operations that have a functional currency different from the Company’s functional and presentation currency are translated into Canadian dollars as follows: (i) (ii) (iii) When a foreign operation is disposed of, the component of other comprehensive income relating to that particular foreign operation is recognized in the consolidated statements of net income and comprehensive income, as part of the gain or loss on sale where applicable. (c) Financial instruments (i) Financial assets The Company initially recognizes a financial asset on the trade date at which the Company becomes a party to the contractual provisions of the instrument. Upon recognition of a financial asset, classification is made based on the business model for managing the asset and the asset’s contractual cash flow characteristics. The financial asset is initially recognized at its fair value and subsequently measured as (i) amortized cost; (ii) fair value through other comprehensive income (“ FVOCI FVTPL The Company derecognizes a financial asset when the contractual cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. Financial assets and liabilities are offset and the net amount presented in the consolidated statements of financial position when, and only when, the Company has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. The Company has classified all of its non-derivative financial assets as financial assets measured at amortized cost, except for the consideration receivable and the holdback receivable, which are classified as FVTPL. The Company has not classified any financial assets as FVOCI. Financial assets measured at amortized cost A non-derivative financial asset is measured at amortized cost when both of the following conditions are met: (i) the asset is held within a business model whose objective is to hold assets in order to collect the contractual cash flows; and (ii) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Such assets are recognized initially at fair value plus any directly attributable transaction costs and measured at amortized cost using the effective interest method subsequent to initial recognition. Financial assets measured at amortized cost are cash and cash equivalents, short-term investments and accounts receivable (ii) Financial liabilities All financial liabilities are recognized initially on the trade date at which the Company becomes a party to the contractual provisions of the instrument. Such financial liabilities are recognized initially at fair value plus any directly attributable transaction costs. All financial liabilities are measured at amortized cost, except for any financial liabilities measured at FVTPL. A financial liability may no longer be reclassified subsequent to initial recognition. Subsequent to initial recognition, financial liabilities are measured at amortized cost using the effective interest method. The Company decognizes a financial liability when its contractual obligations are discharged, cancelled or when they expire. The royalty obligation was recorded at its fair value at the date at which the liability was incurred and subsequently measured at amortized cost using the effective interest rate method at each reporting date. Estimating fair value for this liability required determining the most appropriate valuation model which was dependent on its underlying terms and conditions. This estimate also required determining expected revenue from AGGRASTAT ® (d) Impairment of financial assets Impairment of financial assets is recognized in accordance with a stage-based approach. The first stage begins upon recognition of a financial asset upon which time a loss allowance is recorded and 12-month expected credit losses are recognized in profit or loss. A financial asset is in the second stage of impairment when the credit risk increases significantly and is not considered low upon which time full lifetime expected credit losses are recorded in profit or loss. A financial asset is in the third stage of impairment when the credit risk increases to the point that it is credit impaired. Applicable interest revenue is calculated on the gross carrying amount of financial assets that are in the first or second stage of impairment and on the amortized carrying amount of a financial asset of a financial asset in the third stage of impairment. Impairment losses on financial assets carried at amortized cost are reversed in subsequent periods if the amount of the loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized. (e) Revenue from contracts with customers The Company has two commercially available products, AGGRASTAT® and ZYPITAMAG™ (the “ Products Sales are made subject to certain discounts available for prompt payment, volume discounts, rebates or chargebacks. Revenue from these sales is recognized based on the price specified per the pricing terms of the sales invoices, net of the estimated discounts. Variable consideration is based on historical information, using the expected value method. Revenue is only recognized to the extent that it is highly probable that a significant reversal will not occur. A liability is included within accounts payable and accrued liabilities and is measured for expected payments that will be made to the customers for the discounts in which they are entitled. Sales do not contain an element of financing as sales are made with credit terms within the normal operating cycle of the date of the invoice, which is consistent with market practice. (f) Cash and cash equivalents The Company considers all liquid investments purchased with a maturity of three months or less at acquisition to be cash and cash equivalents, which are carried at amortized cost and are classified at amortized cost. (g) Short-term investments The Company considers all liquid investments purchased with a maturity greater than three months and less than one year at acquisition to be short-term investments, which are carried and classified at amortized cost. (h) Inventories Inventories consist of unfinished product (raw material in the form of API and packaging materials) and finished The cost of inventories is based on the first-in first-out principle, and includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. When the circumstances that previously caused inventories to be written down below cost no longer exist, or when there is clear evidence of an increase in selling prices, the amount of the write-down previously recorded is reversed. (i) Property plant and equipment (i) Recognition and measurement Items of property, plant and equipment are measured at cost less accumulated amortization and accumulated impairment losses and reversals. When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. The costs of the day-to-day servicing of property, plant and equipment are recognized in the consolidated statements of net income and comprehensive income in the period in which they are incurred. (ii) Amortization Amortization is recognized in profit or loss over the estimated useful lives of each part of an item of property, plant and equipment in a manner that most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are as follows: Asset Basis Rate Computers, office equipment, furniture and fixtures Straight-line/Diminishing balance 20% to 25% Leasehold improvements Straight-line Term of lease Amortization methods, useful lives and residual values are reviewed at each period end and adjusted if appropriate. (j) Leases The determination of whether an arrangement is a lease is based on the substance of the arrangement at the inception of the lease. The arrangement is, or contains, a lease if fulfillment of the arrangement is dependent on the use of specific assets and the arrangement conveys a right to use the assets, even if those assets are not explicitly specified in an arrangement. A lease is classified at inception date as a finance or operating lease. A lease that transfers substantially all the risks and rewards incidental to ownership to the Company is classified as a finance lease. Finance leases are capitalized at the commencement of the lease at the inception date fair value of the leased property or, if lower, at the present value of the minimum lease payments. Lease payments are apportioned between finance expense and reduction of the lease liability so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are recognized in finance costs in the consolidated statements of net income and comprehensive income. Leased assets are depreciated over the useful life of each asset. However, if there is no reasonable certainty that the Company will obtain ownership by the end of the lease term, the asset is depreciated over the shorter of the estimated useful life of the asset and the lease term. An operating lease is a lease other than a finance lease. Operating lease payments are recognized as an operating expense in the consolidated statements of net income and comprehensive income on a straight-line basis over the lease term. (k) Intangible assets Intangible assets that are acquired separately are measured at cost less accumulated amortization and accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred. Licenses are amortized on a straight-line basis over the contractual term of the acquired license. Patents are amortized on a straight-line basis over the legal life of the respective patent, ranging from five to twenty years, or its economic life, if shorter. Trademarks are amortized on a straight-line basis over the legal life of the respective trademark, being ten years, or its economic life, if shorter. Customer lists are amortized on a straight-line basis over approximately twelve years, or its economic Amortization on licenses commences when the intangible asset is available for use, which would typically be in connection with the commercial launch of the associated product under the license. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses. The cost of servicing the Company's patents and trademarks are expensed as incurred. The amortization method and amortization period of an intangible asset with a finite useful life are reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates in the consolidated statements of net income and comprehensive income. (l) Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss as incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. No development costs have been capitalized to date. Research and development expenses include all direct and indirect operating expenses supporting the products in development. Clinical trial expenses are a component of the Company’s research and development costs. These expenses include fees paid to contract research organizations, clinical sites, and other organizations who conduct research and development activities on the Company’s behalf. The amount of clinical trial expenses recognized in a period related to clinical agreements are based on estimates of the work performed using an accrual basis of accounting. These estimates incorporate factors such as patient enrolment, services provided, contractual terms, and prior experience with similar contracts. (m) Government assistance Government assistance, in the form of grants, is recognized at fair value where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. Government assistance toward current expenses is recorded as a reduction of the related expenses in the period the expenses are incurred. Government assistance towards property, plant and equipment is deducted from the cost of the related property, plant and equipment. The benefits of investment tax credits for scientific research and experimental development expenditures ("SR&ED") incurred directly by the Company are recognized in the period the qualifying expenditure is made, provided there is reasonable assurance of recoverability. SR&ED investment tax credits receivable are recorded at their net realizable value. (n) Impairment of non-financial assets The Company assesses at each reporting period whether there is an indication that a non-financial asset may be impaired. An impairment loss is recognized when the carrying amount of an asset, or its CGU, exceeds its recoverable amount. Impairment losses are recognized in net income and comprehensive income. A CGU is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets. The recoverable amount is the greater of the asset's or CGU's fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU. In determining fair value less costs to sell, an appropriate valuation model is used. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the CGU to which the asset belongs. For assets other than goodwill, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of amortization, if no impairment loss had been recognized. Goodwill is tested for impairment annually and when circumstances indicate that the carrying value may be impaired. Impairment is determined for goodwill by assessing the recoverable amount of each CGU to which the goodwill relates. When the recoverable amount of the CGU is less than its carrying amount, an impairment loss is recognized. Impairment losses relating to goodwill are not reversed in future periods. (o) Employee benefits (i) Short-term employee benefits Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. (ii) Share-based payment transactions The grant date fair value of share-based payment awards granted to employees is recognized as a personnel expense, with a corresponding increase in equity, over the period that the employees unconditionally become entitled to the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant date fair value of the share-based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcomes. Share-based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity-settled share-based payment transactions. In situations where equity instruments are issued and some or all of the goods or services received by the entity as consideration cannot be specifically identified, they are measured at fair value of the share-based payment. For share-based payment arrangements with non-employees, the expense is recorded over the service period until the options vest. Once the options vest, services are deemed to have been received. Where the terms of an equity-settled transaction award are modified, the minimum expense recognized is the expense as if the terms had not been modified, if the original terms of the award are met. An additional expense is recognized for any modification that increases the total fair value of the share-based payment transaction or is otherwise beneficial to the employee as measured at the date of modification. Where an equity-settled award is cancelled, it is treated as if it vested on the date of the cancellation and any expense not yet recognized for the award [being the total expense as calculated at the grant date] is recognized immediately. This includes any awards where vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award, and designated as a replacement award on the date that it is granted, the cancelled award and new awards are treated as if they were a modification of the original awards. (p) Finance income and finance costs Finance costs comprise interest expense on borrowings which are recognized in net income and comprehensive income using the effective interest rate method, accretion on the royalty obligation, prepayment fees on the early repayment of long-term debt and amortization of deferred debt issue costs using the effective interest rate method, offset by any finance income which is comprised of interest income on funds invested and is recognized as it accrues in net income and comprehensive income, using the effective interest rate method. Foreign currency gains and losses are reported on a net basis. (q) Income taxes The Company and its subsidiaries are generally taxable under the statutes of their country of incorporation. Income tax expense comprises current and deferred taxes. Current taxes and deferred taxes are recognized in profit or loss except to the extent that they relate to a business combination, or items recognized directly in equity or in other comprehensive income. Current taxes are the expected tax receivable or payable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax receivable or payable in respect of previous years. The Company follows the liability method of accounting for deferred taxes. Under this method, deferred taxes are recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred taxes are not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss, and differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future. In addition, deferred taxes are not recognized for taxable temporary differences arising on the initial recognition of goodwill. Deferred taxes are measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the tax laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax assets and liabilities, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax assets and liabilities on a net basis or their tax assets and liabilities will be realized simultaneously. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. The Company has provided for income taxes, including the impacts of tax legislation in various jurisdictions, in accordance with guidance issued by accounting regulatory bodies, the Canada Revenue Agency, the U.S. Internal Revenue Service, the Barbados Revenue Authority, the Mauritius Revenue Authority, as well as other state and local governments through the date of the issuance of these consolidated financial statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results. While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time. The Company and its subsidiaries file federal income tax returns in Canada, the United States, Barbados and other foreign jurisdictions, as well as various provinces and states in Canada and the United States. The Company and its subsidiaries have open tax years, primarily from 2009 to 2018, with significant taxing jurisdictions, including Canada, the United States and Barbados. These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years may remain open indefinitely. Tax benefits acquired as part of a business combination, but not satisfying the criteria for separate recognition at that date, would be recognized subsequently if information about facts and circumstances changed. The adjustment would either be treated as a reduction to goodwill if it occurred during the measurement period or in profit or loss, when it occurs subsequent to the measurement period. (r) Earnings per share The Company presents basic earnings per share ("EPS") data for its common voting shares. Basic EPS is calculated by dividing the profit or loss attributable to common voting shareholders of the Company by the weighted average number of common voting shares outstanding during the period, adjusted for the Company's own shares held. Diluted EPS is computed similar to basic EPS except that the weighted average shares outstanding are increased to include additional shares for the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options and warrants were exercised and that the proceeds from such exercise were used to acquire common shares at the average market price during the reporting periods. (s) Business combinations and goodwill Business combinations are accounted for using the acquisition method. The consideration for an acquisition is measured at the fair values of the assets transferred, the liabilities assumed and the equity interests issued at the acquisition date. Transaction costs that are incurred in connection with a business combination, other than costs associated with the issuance of debt or equity securities, are expensed as incurred. Identified assets acquired and liabilities and contingent liabilities assumed are measured initially at fair values at the date of acquisition. On an acquisition-by-acquisition basis, any non-controlling interest is measured either at fair value of the non-controlling interest or at the fair value of the proportionate share of the net assets acquired. Contingent consideration is measured at fair value on acquisition date and is included as part of the consideration transferred. The fair value of the contingent consideration liability is remeasured at each reporting date with the corresponding gain or loss being recognized in profit or loss. Goodwill is initially measured at cost, being the excess of fair value of the cost of the business combinations over the Company’s share in the net fair value of the acquiree’s identifiable assets, liabilities and contingent liabilities. Any negative difference is recognized directly in the consolidated statements of net income and comprehensive income. If the fair values of the assets, liabilities and contingent liabilities can only be calculated on a provisional basis, the business combination is recognized using provisional values. Any adjustments resulting from the completion of the measurement process are recognized within twelve months of the date of the acquisition.

New standards and interpretatio

New standards and interpretations	12 Months Ended
	Dec. 31, 2018
Disclosure of initial application of standards or interpretations [abstract]
New standards and interpretations	4. New standards and interpretations The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective. Set out below is the impact of the mandatory adoption of new standards: IFRS 9, Financial Instruments: Classification and Measurement Effective January 1, 2018, the Company has adopted IFRS 9 retrospectively. Prior periods were not restated and no material changes resulted from adoption of this new standard. IFRS 9 introduced a revised model for classification and measurement, which has resulted in several financial instrument reclassification changes by the Company. There were no quantitative impacts from adoption of IFRS 9. Upon recognition of a financial asset, classification is made based on the business model for managing the asset and the asset’s contractual cash flow characteristics. The financial asset is initially recognized at its fair value and subsequently classified and measured as (i) amortized cost; (ii) fair value through other comprehensive income (“FVOCI”); or (iii) fair value through profit or loss (“FVTPL”). Financial assets are classified as FVTPL if they have not been classified as measured at amortized cost or FVOCI. Upon initial recognition of an equity instrument that is not held-for-trading, the Company may irrevocable designate the presentation of subsequent changes in the fair value of such equity instrument as FVTPL. The Company recognizes a financial liability on the trade date in which it becomes a party to the contractual provisions of the instrument at fair value plus any directly attributable costs. Financial liabilities are subsequently measured at amortized cost or FVTPL, and are not subsequently reclassified. An “expected credit loss” impairment model applies which requires a loss allowance to be recorded on financial assets measured at amortized cost based on their expected credit losses. An estimate is made to determine the present value of future cash flows associated with the asset, and if required, an impairment loss is recorded. The impairment loss reduces the carrying value of the impaired financial asset to the value of the estimated present value of the future cash flows associated with the asset, discounted at the financial asset’s original effective interest rate is recorded either directly or through the use of an allowance account and the resulting impairment loss is recorded in profit or loss. Below is a summary showing the classification and measurement basis for the Company’s financial instruments as a result of the adoption of IFRS on January 1, 2018 with a comparison to the previous classification under IAS 39: Financial instrument Classification under IAS 39 Classification under IFRS 9 Financial assets Cash and equivalents Loans and receivables Amortized cost Short-term investments Loans and receivables Amortized cost Accounts receivable Loans and receivables Amortized cost Consideration receivable Loans and receivables FVTPL Holdback receivable Loans and receivables FVTPL Financial liabilities Accounts payable and accrued liabilities Other financial liabilities Amortized cost Accrued transaction costs Other financial liabilities Amortized cost Current portion of royalty obligation Other financial liabilities Amortized cost Royalty obligation Other financial liabilities Amortized cost License fee payable Other financial liabilities Amortized cost Other long-term liability Other financial liabilities Amortized cost IFRS 15, Revenue from Contracts with Customers Effective January 1, 2018, the Company has adopted IFRS 15 retrospectively. Prior periods were not restated and no material changes resulted from adoption of this new standard. IFRS 15 and provides a model for the recognition and measurement of gains or losses from sales of some non-financial assets. The core principle is that revenue is recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The adoption of the standard will also result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and improve guidance for multiple-element arrangements. There were no quantitative impacts from adoption of IFRS 15. IFRS 2, Share-based Payments Effective January 1, 2018, the Company has adopted the required amendments to IFRS 2, which provides requirements on the accounting for the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments, share-based payment transactions with a net settlement feature for withholding tax obligations, and a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity settled. There were no quantitative impacts from adoption of the amendments to IFRS 2. New standard not yet adopted As at , the following standard has been issued but is not yet effective: IFRS 16, Leases In January 2016, the IASB issued IFRS 16 which requires lessees to recognize assets and liabilities for most leases. Lessees will have a single accounting model for all leases, with certain exemptions. The new standard is effective January 1, 2019, with limited early application permitted. The new standard permits lessees to use either a full retrospective or a modified retrospective approach on transition for leases existing at the date of transition, with options to use certain transition reliefs. The Company has evaluated the standard and does not expect a material impact on its consolidated financial statements as a result of its adoption.

Discontinued operations

Discontinued operations	12 Months Ended
	Dec. 31, 2018
Discontinued Operations [Abstract]
Discontinued operations	5. Discontinued operations On October 2, 2017, the Company sold its interests in Apicore (the “Apicore Sale Transaction”) to an arm’s-length, pharmaceutical company (the “Buyer”). The Company acquired Apicore in a series of transactions occurring between July 3, 2014 and July 12, 2017 Under the Apicore Sale Transaction, the Company received a payment of U.S. $57,623,125 (Cdn - $72,057,718) upon the closing of the transaction. Additional working capital and deferred payments of U.S. $52,886,588 (Cdn - $65,234,555) were received subsequent to December 31, 2017 as part of the Apicore Sales Transaction and were recorded as consideration receivable as at December 31, 2017. Additionally, a contingent payment in the form of an earn-out based on the achievement of certain financial results by Apicore for the year ended December 31, 2017 could have been received, however the financial results specified under the Apicore Sales Transaction were not achieved. As a result, no amount has been recorded in the consolidated financial statements pertaining to this potential earn-out payment. Additionally, under the Apicore Sale Transaction, the Buyer held an option to acquire Apicore’s Indian operations for a fixed price until December 31, 2017. This option lapsed without exercise and the Company sold Apicore’s Indian operations, to a company owned by the former President and Chief Executive Officer of Apicore Inc. in January of 2018 with the net assets held for sale being released from accounts payable and accrued liabilities at that time. Set out below is the financial performance for years ended December 31, 2018, 2017 and 2016 relating to the Apicore business: Year ended December 31 2018 2017 2016 Revenue $ - $ 22,759,385 $ 7,798,838 Expenses - (47,936,485 ) (9,263,926 ) Revaluation of long-term derivative - - 20,560,440 Gain on step acquisition - - 4,895,573 (Loss) income from discontinued operations $ - $ (25,177,100 ) $ 23,990,925 Income tax recovery (expense) - 1,847,055 (632,607 ) Loss (income) after income tax recovery (expense) $ - (23,330,045 ) 23,358,318 Gain on disposition of the Apicore business - 55,254,236 - Income from discontinued operations $ - $ 31,924,191 $ 23,358,318 Set out below is the cash flow information for the years ended December 31, 2018, 2017 and 2016 relating to the Apicore business: Year ended December 31 2018 2017 2016 Net cash flows used in operating activities $ - $ 5,210,341 $ (1,295,487 ) Net cash flows from (used in) investing activities - 54,326,360 (421,077 ) Net cash flows from (used in) financing activities - (80,944,373 ) 44,294,204 Net cash flows used in discontinued operations $ - $ (21,407,672 ) $ 42,577,640 As previously described, the Company retained ownership in Apicore’s Indian operations until the lapse of the Buyer Option and during January of 2018, Apicore’s Indian operations were sold to a company owned by the former President and Chief Executive Officer of Apicore Inc. Immediately before the classification as discontinued operations, the recoverable amount was estimated for certain items and no impairment loss was identified. As at December 31, 2017, a write-down of $1,791,484 was recognized to reduce the carrying amount of the assets in the disposal group to their fair value less costs to sell, which totaled $7,076,548. This impairment was recognized in discontinued operations in the statements net income and comprehensive income for the year ended December 31, 2017.

Accounts receivable

Accounts receivable	12 Months Ended
	Dec. 31, 2018
Trade and other receivables [abstract]
Accounts receivable	6. Accounts receivable As at December 31 2018 2017 Trade accounts receivable $ 9,677,847 $ 8,496,281 Other accounts receivable 1,086,732 91,974 $ 10,764,579 $ 8,588,255 As at December 31, 2018, there were three customers with amounts owing greater than 10% of the Company’s accounts receivable which totaled 91% in aggregate (Customer A – 47%, Customer B – 22%, Customer C – 22%). As at December 31, 2017, there were three customers with amounts owing greater than 10% of the Company’s accounts receivable which totaled 96% in aggregate (Customer A – 41%, Customer B – 32%, Customer C – 23%).

Inventories

Inventories	12 Months Ended
	Dec. 31, 2018
Disclosure Of Inventories [Abstract]
Inventories	7. Inventories As at December 31 2018 2017 Finished product available-for-sale $ 2,936,883 $ 2,058,776 Unfinished product and packaging materials 1,302,384 1,016,230 $ 4,239,267 $ 3,075,006 Inventories expensed as part of cost of goods sold during the year ended December 31, 2018 amounted to $3,861,745 (2017 – $3,079,397; 2016 – $2,482,986). During the year ended December 31, 2018, the Company wrote-off inventory of $94,517 (2017 – $385,289; 2016 – recovery of $108,817) that had expired or was otherwise unusable.

Property, plant and equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about property, plant and equipment [abstract]
Property, plant and equipment	8. Property, plant and equipment Cost Land Building Computer Machinery Leasehold Total At December 31, 2016 $ 2,316,979 $ 2,122,687 $ 2,439,071 $ 2,798,482 $ 1,003,490 $ 10,680,709 Additions - 82,163 675,788 298,754 - 1,056,705 Transfers to assets held for resale (2,317,273 ) (2,900,284 ) (3,319,298 ) (4,572,065 ) (790,814 ) (13,899,734 ) Effect of movements in exchange rates 294 695,434 632,604 1,474,829 (56,333 ) 2,746,828 At December 31, 2017 $ - $ - $ 428,165 $ - $ 156,343 $ 584,508 Additions - - 185,682 - 11,812 197,494 Effect of movements in exchange rates - - 12,078 - - 12,078 Dispositions - - (156,280 ) - - (156,280 ) At December 31, 2018 $ - $ - $ 469,645 $ - $ 168,155 $ 637,800 Accumulated amortization and impairment losses Land Building Computer Machinery Leasehold Total At December 31, 2016 $ - $ 21,408 $ 250,261 $ 67,541 $ 40,860 $ 380,070 Amortization - 291,638 339,358 384,486 157,537 1,173,019 Transfers to assets held for resale - (306,761 ) (286,632 ) (443,746 ) (112,213 ) (1,149,352 ) Effect of movements in exchange rates - (6,285 ) (21,720 ) (8,281 ) (4,565 ) (40,851 ) At December 31, 2017 $ - $ - $ 281,267 $ - $ 81,619 $ 362,886 Amortization - - 75,471 - 27,736 103,207 Effect of movements in exchange rates - - 11,974 - - 11,974 Dispositions - - (156,280 ) - - (156,280 ) At December 31, 2018 $ - $ - $ 212,432 $ - $ 109,355 $ 321,787 Carrying amounts Land Building Computer Machinery Leasehold Total At December 31, 2017 $ - $ - $ 146,898 $ - $ 74,724 $ 221,622 At December 31, 2018 $ - $ - $ 257,213 $ - $ 58,800 $ 316,013 During the year ended December 31, 2018, amortization of property, plant and equipment totaling $103,207 (2017 – $97,794; 2016 – $83,284) is included within selling, general and administrative expenses on the consolidated statements of net income and comprehensive income. For the years ended December 31, 2017 and 2016, amortization of property, plant and equipment totaling $1,075,225 and $105,724, respectively is recorded within discontinued operations.

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about intangible assets [abstract]
Intangible assets	9. Intangible assets Cost Licenses Patents Trademarks Customer Approved Acquired in Total At December 31, 2016 $ - $ 25,012,530 $ 4,296,192 $ 7,472,143 $ 1,505,664 $ 83,720,025 $ 122,006,554 Additions 2,383,550 - - - - - 2,383,550 Impairment (635,721 ) - - - - - (635,721 ) Transfers to assets held for resale - (9,122,874 ) - (6,267,525 ) (1,405,541 ) (78,152,819 ) (94,948,759 ) Effect of movements in exchange rates 8,471 (1,650,944 ) (282,211 ) (496,269 ) (100,123 ) (5,567,206 ) (8,088,282 ) At December 31, 2017 $ 1,756,300 $ 14,238,712 $ 4,013,981 $ 708,349 $ - $ - $ 20,717,342 Effect of movements in exchange rates 153,580 1,245,105 351,004 61,943 - - 1,811,632 At December 31, 2018 $ 1,909,880 $ 15,483,817 $ 4,364,985 $ 770,292 $ - $ - $ 22,528,974 Accumulated Licenses Patents Trademarks Customer Approved Acquired in Total At December 31, 2016 $ - $ 15,321,230 $ 4,296,192 $ 814,101 $ 12,548 $ 697,666 $ 21,141,737 Amortization - 637,406 - 437,904 98,203 5,460,444 6,633,957 Transfers to assets held for resale - (684,216 ) - (470,064 ) (105,416 ) (5,861,461 ) (7,121,157 ) Effect of movements in exchange rates - (1,035,708 ) (282,211 ) (73,592 ) (5,335 ) (296,649 ) (1,693,495 ) At December 31, 2017 $ - $ 14,238,712 $ 4,013,981 $ 708,349 $ - $ - $ 18,961,042 Amortization 195,977 - - - - - 195,977 Effect of movements in exchange rates 8,653 1,245,105 351,004 61,943 - - 1,666,705 At December 31, 2018 $ 204,630 $ 15,483,817 $ 4,364,985 $ 770,292 $ - $ - $ 20,823,724 Carrying amounts Licenses Patents Trademarks Customer Approved Acquired in Total At December 31, 2017 $ 1,756,300 $ - $ - $ - $ - $ - $ 1,756,300 At December 31, 2018 $ 1,705,250 $ - $ - $ - $ - $ - $ 1,705,250 As at December 31, 2018, the Company has recorded $545,680 (2017 - $501,800) within accounts payable and accrued liabilities relating to the current portion of license fees payable relating to the Zypitamag license acquired during the year ended December 31, 2017. The Company has considered indicators of impairment as at December 31, 2018 and 2017. The Company did not record any write-down of intangible assets during the year ended December 31, 2018. During the year ended December 31, 2017 the Company recorded a write-down of intangible assets totaling $635,721 pertaining to a license acquired during the year ended December 31, 2017. As at December 31, 2018, intangible assets pertaining to AGGRASTAT ® For the year ended December 31, 2018, amortization on the license totaling $195,977 is recorded within cost of goods sold. For the years ended December 31 2017, there was no amortization of intangible recorded within net income from continuing operations. For the year ended December 31, 2016, amortization of intangible assets relating to AGGRASTAT ® For the years ended December 31, 2017 and 2016, amortization of the acquired intangible assets totaling $6,633,957 and $841,754, respectively, was recognized within loss from discontinued operations.

Holdback receivable

Holdback receivable	12 Months Ended
	Dec. 31, 2018
Holdback Receivable [Abstract]
Holdback receivable	10. Holdback receivable The holdback receivable of US$10 million originated on October 2, 2017 as a part of the Apicore Sale Transaction described in note 5. The holdback receivable was initially recorded at its fair value of $11,940,736 and subsequently is measured at FVTPL. The other long-term liability, totalling $1,200,608 (2017 - $1,135,007) is payable to the former President and Chief Executive Officer of Apicore upon receipt of the holdback receivable. On February 13, 2019, the Company received notice from the Buyer in the Apicore Sales Transaction of potential claims against the holdback receivable in respect of representations and warranties under the Apicore Sales Transaction with the maximum exposure In consideration of the

Royalty obligation

Royalty obligation	12 Months Ended
	Dec. 31, 2018
Royalty Obligation [Abstract]
Royalty obligation	11. Royalty obligation On July 18, 2011, the Company settled its then existing long-term debt with Birmingham Associates Ltd. ("Birmingham"), an affiliate of Elliott Associates L.P., in exchange for i) $4,750,000 in cash; ii) 2,176,003 common shares of the Company; and iii) a royalty on future AGGRASTAT ® ® ® In accordance with the terms of the agreement, if the Company were to dispose of its AGGRASTAT ® The royalty obligation was recorded at its fair value at the date at which the liability was incurred, estimated to be $901,915, and subsequently measured at amortized cost using the effective interest rate method at each reporting date. This resulted in a carrying value as at December 31, 2018 of $3,530,558 (2017 $4,449,012) of which $1,495,548 (2017 $1,537,202) represents the current portion of the royalty obligation. The net change in the royalty obligation for the year ended December 31, 2018 of $355,287 (2017 $747,540; 2016 $2,271,436) is recorded within finance (income) expense on the consolidated statements of net income and comprehensive income. Royalties for the year ended December 31, 2018 totaled $1,654,380 (2017 $1,242,587; 2016 $1,795,089) with payments made during the year ended December 31, 2018 of $1,538,766 (2017 $1,829,295; 2016 $1,712,390).

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2018
Disclosure Of Capital Stock [Abstract]
Capital Stock	12. Capital Stock (a) Authorized The Company has authorized share capital of an unlimited number of common voting shares, an unlimited number of Class A common shares and an unlimited number of preferred shares. The preferred shares may be issued in one or more series, and the directors may fix prior to each series issued, the designation, rights, privileges, restrictions and conditions attached to each series of preferred shares. (b) Shares issued and outstanding Shares issued and outstanding are as follows: Number of Common Shares Amount Balance, December 31, 2016 15,532,408 $ 124,700,345 Shares issued upon exercise of stock options (12(c)) 207,950 869,703 Shares issued upon exercise of warrants (12(d)) 41,969 163,679 Balance, December 31, 2017 15,782,327 $ 125,733,727 Shares issued upon exercise of stock options (12(c)) 206,885 654,711 Shares repurchased and cancelled under a normal course issuer bid (*) (441,400 ) (3,501,333 ) Balance, December 31, 2018 15,547,812 $ 122,887,105 (*) During the year ended December 31, 2018 the Company repurchased and cancelled 441,400 common shares. The aggregate price paid for these common shares totaled $3,021,340. As a result of the NCIB, during the year ended December 31, 2018 the Company recorded $479,993 directly in its retained deficit representing the difference between the aggregate price paid for these common shares and a reduction of the Company’s share capital totaling $3,501,333. Subsequent to December 31, 2018, the Company repurchased an additional 159,900 common shares to be cancelled for an aggregate cost of $999,826. (c) Stock option plan The Company has a stock option plan which is administered by the Board of Directors of the Company with stock options granted to directors, management, employees and consultants as a form of compensation. The number of common shares reserved for issuance of stock options is limited to a maximum of 2,934,403 common shares of the Company at any time. The stock options generally have a maximum term of between five and ten years and vest within a five-year period from the date of grant. Changes in the number of options outstanding during the year ended December 31, 2018 is as follows: Year ended December 31, 2018 Options Weighted average exercise price Balance, beginning of period 1,602,127 $ 3.58 Granted 200,000 7.25 Exercised (206,885 ) (1.76 ) Forfeited, cancelled or expired (200,600 ) (6.85 ) Balance, end of period 1,394,642 $ 3.91 Options exercisable, end of period 1,044,892 $ 2.80 Changes in the number of options outstanding during the years ended December 31, 2017 and 2016 are as follows: Year ended December 31 2017 2016 Options Weighted average exercise price Options Weighted average exercise price Balance, beginning of period 1,387,000 $ 2.37 2,277,126 $ 1.90 Granted 476,000 7.20 265,025 6.16 Exercised (207,950 ) (2.50 ) (1,069,434 ) (1.72 ) Forfeited, cancelled or expired (52,923 ) (8.58 ) (85,717 ) (9.59 ) Balance, end of period 1,602,127 $ 3.58 1,387,000 $ 2.37 Options exercisable, end of period 1,231,127 $ 2.50 1,387,000 $ 2.37 Options outstanding at December 31, 2018 consist of the following: Range of exercise prices Number outstanding Weighted average remaining contractual life Options outstanding weighted average exercise price Number exercisable $0.30 185,000 4.35 years $ 0.30 185,000 $0.31 - $1.00 5,334 0.29 years $ 0.60 5,334 $1.01 - $3.00 549,433 3.35 years $ 1.59 549,433 $3.01 - $5.00 32,500 1.90 years $ 3.90 32,500 $5.01 - $7.30 622,375 3.89 years $ 7.06 272,625 $0.30 - $7.30 1,394,642 3.68 years $ 3.91 1,044,892 Compensation expense related to stock options granted during the period or from previous periods under the stock option plan for the year ended December 31, 2018 is $1,022,175 (2017 – $490,769; 2016 – $1,340,001). The compensation expense was determined based on the fair value of the options at the date of measurement using the Black-Scholes option pricing model. The expected life of stock options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the options is indicative of future trends, which may not necessarily be the actual outcome. The compensation expense for the years ended December 31, 2018, 2017 and 2016 was determined based on the fair value of the options at the date of measurement using the Black-Scholes option pricing model: Years ended December 31: 2018 2017 2016 Expected option life 4.4 years 4.5 years 4.8–5.0 years Risk free interest rate 1.92%-2.04% 1.71 % 0.52%-0.67% Dividend yield Nil nil nil Expected volatility 85.14%-93.72% 80.44 % 115.59%-117.56% Additionally, prior to its disposal Apicore had a stock option plan and at the December 1, 2016 acquisition date, there were 897,500 options to purchase Class E common stock of Apicore Inc. outstanding. 497,500 options became fully vested on the change in control with the right to put the outstanding Apicore Class E shares and options to the Company upon the change in control. The remaining Apicore stock options outstanding of 400,000 were unaffected by the change of control and fully vested during 2017. The value of the put option was initially recorded as a liability to repurchase Apicore Class E shares on the consolidated statements of financial position and the value of the remaining options was recorded as non-controlling interest within equity. During the year ended December 31, 2017, employees and former directors of Apicore exercised 292,500 stock options to acquire 292,500 Class E common shares of Apicore for gross proceeds to the Company of U.S.$280,125. These shares, as well as 112,500 Class E common shares previously issued for gross proceeds of U.S.$48,375 were then purchased by the Company upon the employees and former directors exercising their put right to the Company. This resulted in the Company acquiring 405,000 Class E common shares of Apicore for a total cost of U.S.$1,974,772 (Cdn - $2,690,383) during 2017. As a result of the employees and former directors exercising their put right to the Company, the liability to repurchase Apicore Class E common shares on the consolidated statements of financial position was reduced. On July 3, 2017, the remaining employee put options over 117,500 Class E shares, to be issued upon the exercise of stock options, of Apicore expired without being exercised by the employees and the value of these options, totaling $615,381, was reclassified as a non-controlling interest. As a result, there remained 517,500 stock options in Apicore Inc. outstanding prior to the sale transaction which occurred on October 2, 2017. During the year ended December 31, 2017, the Company recorded $132,346 (2016 – $60,240), respectively of stock-based compensation expense within the loss from discontinued operations on the consolidated statements of net income and comprehensive income relating to stock options in Apicore. (d) Warrants On November 17, 2016 in connection with a term loan entered into to fund an acquisition, the Company issued 900,000 warrants to the lenders, exercisable for a 48-month period following the issuance of the loan at a price of $6.50 per share. The fair value of the warrants issued in connection with the loan was $2,065,500 net of its pro-rata share of financing costs of $116,695 and were recorded in equity with a corresponding balance recorded as deferred financing costs which is netted against the associated long-term debt on the consolidated statements of financial position as at December 31, 2017. Changes in the number of Canadian dollar denominated warrants outstanding during the years ended December 31, 2018, 2017 and 2016 are as follows: Years ended December 31 2018 2017 2016 Warrants Weighted average exercise price Warrants Weighted average exercise price Warrants Weighted average exercise price Balance, beginning of period 900,000 $ 6.50 941,969 $ 6.31 59,775 $ 2.20 Granted - - - - 900,000 6.50 Exercised - - (41,969 ) (2.20 ) (17,806 ) (2.20 ) Balance, end of period 900,000 $ 6.50 900,000 $ 6.50 941,969 $ 6.31 Warrants exercisable, end of period 900,000 $ 6.50 900,000 $ 6.50 941,969 $ 6.31 The fair value of the warrants issued during the year ended December 31, 2016 was determined at the date of measurement using a Black-Scholes pricing model with the following assumptions: Years ended December 31 2016 Expected option life 4.0 years Risk-free interest rate 0.85 % Dividend yield nil Expected volatility 120.40 % (e) Per share amounts The following table reflects the calculation of basic earnings per share for the years ended December 31, 2018, 2017 and 2016: Year ended December 31 2018 2017 2016 Net earnings before discontinued operations $ 0.25 $ 0.74 $ 0.24 Earnings from discontinued operations, net of tax - 2.04 1.56 $ 0.25 $ 2.78 $ 1.80 The following table reflects the calculation of diluted earnings per share for the years ended December 31, 2018, 2017 and 2016: Year ended December 31 2018 2017 2016 Net earnings before discontinued operations $ 0.24 $ 0.63 $ 0.21 Earnings from discontinued operations, net of tax - 1.76 1.35 $ 0.24 $ 2.39 $ 1.56 The following table reflects the income used in the basic earnings per share computations for the years ended December 31, 2018, 2017 and 2016: Year ended December 31 2018 2017 2016 Net earnings before discontinued operations $ 3,925,639 $ 11,496,693 $ 3,624,323 Earnings from discontinued operations, net of tax - 31,924,191 23,358,318 $ 3,925,639 $ 43,420,884 $ 26,982,641 The following table reflects the income (and share data used in the denominator of the basic and diluted earnings per share computations for the years ended December 31, 2018, 2017 and 2016: Year ended December 31 2018 2017 2016 Weighted average shares outstanding for basic earnings per share 15,791,396 15,636,853 15,002,005 Effects of dilution from: Stock options 772,267 1,601,227 1,372,427 Warrants - 900,000 941,969 Weighted average shares outstanding for diluted earnings per share 16,563,663 18,138,080 17,316,401 Effects of dilution from 622,375 stock options (2017 – 900, 2016 – 14,573) and 900,000 warrants (2017 – nil and 2016 – nil) were excluded in the calculation of weighted average shares outstanding for diluted earnings per share before discontinued operations for the year ended December 31, 2018 as their exercise prices exceed the Company’s share price on the TSX-V at December 31, 2018.

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2018
Income Taxes [Abstract]
Income taxes	13. Income taxes The Company recognized current income tax expense of $677,900 for the year ended December 31, 2018 (2017 – recovery of $9,392,836; 2016 – expense of $501,315).and a deferred income tax expense of $218,976 for the year ended December 31, 2018 (2017 – expense of $333,187; 2016 – recovery of $331,095). As at December 31, 2018 and 2017, deferred tax assets and liabilities have been recognized with respect to the following items: As at December 31 2018 2017 Deferred tax assets Non-capital loss carryforwards $ 127,176 $ 326,108 Total deferred tax assets $ 127,176 $ 326,108 As at December 31, 2018 and 2017, Canadian deferred tax assets have not been recognized with respect to the following table. The scientific research and experimental development deferred tax assets expire between 2025 and 2028. As at December 31 2018 2017 Deferred tax assets Scientific research and experimental development $ 3,237,000 $ 3,574,000 Holdback receivable 199,000 - Other 159,000 315,000 Total deferred tax assets $ 3,595,000 $ 3,889,000 The reconciliation of the Canadian statutory rate to the income tax rate applied to the net income before discontinued operations for the years ended December 31, 2018, 2017 and 2016 to the income tax expense is as follows: Year ended December 31 2018 2017 2016 Income (loss) for the year Canadian $ 3,439,883 $ (2,178,334 ) $ (4,012,706 ) Foreign 1,382,632 4,615,378 7,807,249 $ 4,822,515 $ 2,437,044 $ 3,794,543 Year ended December 31 2018 2017 2016 Canadian federal and provincial income taxes at 27% (2017 – 27%; 2016 – 27%) $ (1,302,000 ) $ (658,000 ) $ (1,025,000 ) Permanent differences and other items 26,000 (335,000 ) (758,000 ) Foreign tax rate in foreign jurisdictions 85,000 656,000 2,159,000 Change in unrecognized deferred tax assets 294,000 9,397,000 (546,000 ) $ (897,000 ) $ 9,060,000 $ (170,000 ) The foreign tax rate differential is the difference between the Canadian federal and provincial statutory income tax rate and the tax rates in Barbados (2.50 %), Mauritius (15.00%), Ireland (12.50%) At December 31, 2018, the Company has the following Barbados losses available for application in future years: 2019 $ 2,478,000 2020 1,271,000 2022 1,339,000 $ 5,088,000

Finance income (expense)

Finance income (expense)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Finance Cost Income [Abstract]
Finance income (expense)	14. Finance income (expense) During the years ended December 31, 2018, 2017 and 2016 the Company earned finance income (incurred finance expense) as follows: Year ended December 31 2018 2017 2016 Interest income $ 1,114,676 $ 47,447 $ 30,452 Accretion of royalty obligation (355,287 ) (747,540 ) (2,271,436 ) Accretion on holdback receivable 325,522 - - Interest on MIOP loan - (105,670 ) (218,867 ) Bank charges and other interest (23,979 ) (31,698 ) (20,224 ) Change in fair value of warrant liability - - 1,161 $ 1,060,932 $ (837,461 ) $ (2,478,914 ) During the years ended December 31, 2018, 2017 and 2016, the Company received (paid) finance income (expense) as follows: Year ended December 31 2018 2017 2016 Interest received $ 279,098 $ 47,447 $ 30,452 Interest paid on MIOP loan - (88,828 ) (186,467 ) Other interest, net and banking fees (23,979 ) (31,698 ) (20,224 ) $ 255,119 $ 73,079 $ 176,239

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2018
Disclosure Of Commitment And Contingencies [Abstract]
Commitments and contingencies	15. Commitments and contingencies (a) Commitments As at December 31, 2018, and in the normal course of business, the Company has obligations to make future payments representing contracts and other commitments that are known and committed as follows: 2019 $ 4,005,841 2020 2,240,096 2021 1,274,935 2022 1,294,288 2023 204,630 Thereafter 204,630 $ 9,224,420 The Company has entered into a manufacturing and supply agreement to purchase a minimum quantity of AGGRASTAT ® ® Effective November 1, 2014, the Company entered into a sub-lease with Genesys Venture Inc. (“GVI”) to lease office space at a rate of $170,000 per annum for three years ending October 31, 2017. The lease was amended on May 1, 2016 and increased the leased area covered under the lease agreement at a rate of $212,000 per annum until October 31, 2019. The leased area covered under the lease was again increased, effective November 1, 2018 at a rate of $306,400 per annum until the end of the term of the lease. Subsequent to December 31, 2018, effective January 1, 2019, the Company renewed its business and administration services agreement with GVI, as described in note 16(b), under which the Company is committed to pay $7,083 per month or $85,000 per year for a one-year term. Contracts with contract research organizations are payable over the terms of the associated agreements and clinical trials and timing of payments is largely dependent on various milestones being met, such as the number of patients recruited, number of monitoring visits conducted, the completion of certain data management activities, trial completion, and other trial related activities. On October 31, 2017, the Company acquired an exclusive license to sell and market PREXXARTAN ® ® ® described in note 15(d) and is recorded within accounts payable and accrued liabilities on the consolidated statements of financial position. On December 14, 2017 and subsequently updated on March 7, 2018, the Company announced it had acquired an exclusive license to sell and market a branded cardiovascular drug, TM TM (b) Guarantees The (c) Royalties As a part of the Birmingham debt settlement described in note 11, beginning on July 18, 2011, the Company is obligated to pay a royalty to Birmingham based on future commercial AGGRASTAT ® ® . Birmingham has a one-time option to switch the royalty payment from AGGRASTAT ® $1,242,587; 2016 $1,795,089) with payments made during the year ended December 31, 2018 of $1,538,766 (2017 $1,829,295; 2016 $1,712,390). The Company is obligated to pay royalties on any future commercial net sales of ® to the licensor of ® . To date, no royalties are due and/or payable. (d) Contingencies In the normal course of business, the Company may from time to time be subject to various claims or possible claims. Although management currently believes there are no claims or possible claims that if resolved would either individually or collectively result in a material adverse impact on the Company’s financial position, results of operations, or cash flows, these matters are inherently uncertain and management’s view of these matters may change in the future. During 2018, the Company was named in a civil claim in Florida from the third-party manufacturer of PREXXARTAN ® ® On September 10, 2015, the Company submitted a supplemental New Drug Application (“sNDA”) to the FDA to expand the label for AGGRASTAT ® During 2015, the Company began a development project of a cardiovascular generic drug in collaboration with Apicore. The Company has entered into a supply and development agreement under which the Company holds all commercial rights to the drug. In connection with this project, the Company is obligated to pay Apicore 50% of net profit from the sale of this drug.

Related party transactions

Related party transactions	12 Months Ended
	Dec. 31, 2018
Disclosure of transactions between related parties [abstract]
Related party transactions	16. Related party transactions (a) Key management personnel compensation Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company. The Board of Directors, President and Chief Executive Officer and Chief Financial Officer are key management personnel for all periods. The Vice-President, Commercial Operations was considered key management personnel until the conclusion of his employment in September 2017 and for the 2018 periods, a new Vice-President, Commercial Operations was hired effective January 8, 2018 and is included in key management personnel from the effective date of his hire. Beginning in December 2016 and ending of October 2, 2017, the President and Chief Executive Officer of Apicore, was considered key management personnel. On May 9, 2016, the Company announced that the employment agreement with the Company’s then President and Chief Operating Officer had been terminated, effective immediately. For the year ended December 31, 2016, the now former President and Chief Operating Officer was included in key management personnel. The compensation pertaining to the President and Chief Executive Officer of Apicore has been included in the income from discontinued operations in the consolidated statements of net income and comprehensive income for the years ended December 31, 2017 and 2016 and his compensation has been excluded from the table below. Included in the table below is $750,000 relating to transaction bonuses which is included within the income from discontinued operations for the year ended December 31, 2017 on the consolidated statement net income and comprehensive income. In addition to their salaries, the Company also provides non-cash benefits and participation in the Stock Option Plan. The following table details the compensation paid to key management personnel: Year ended December 31 2018 2017 2016 Salaries, fees and short-term benefits $ 769,636 $ 1,463,106 $ 839,735 Termination benefits - - 221,624 Share-based payments 669,371 139,189 145,398 $ 1,439,007 $ 1,602,295 $ 1,206,757 As at December 31, 2018, the Company has $4,683 (2017 $1,000; 2016 $13,279) recorded within accounts payable and accrued liabilities relating to amounts payable to the members of the Company's Board of Directors for services provided. On May 9, 2016, the Company announced that the employment agreement with the Company’s President and Chief Operating Officer had been terminated, effective immediately. Included within selling, general and administrative expenses for the year ended December 31, 2016 is $221,624 pertaining to severance for the former President and Chief Operating Officer. All amounts pertaining to this severance were paid during 2016 and there is no additional liability in this regard. (b) Transactions with related parties Directors and key management personnel control 17% of the voting shares of the Company as at December 31, 2018 (2017 – 16%). During the year ended December 31, 2018 the Company paid GVI, a company controlled by the Chief Executive Officer, a total of $85,000 (2017 – $85,000; 2016 – $85,000) for business administration services, $227,733 (2017 – $212,000; 2016 – $222,500) in rental costs and $46,950 (2017 – $43,800; 2016 – $41,975) for commercial and information technology support services. As described in note 15(a), the business administration services summarized above are provided to the Company through a consulting agreement with GVI. Clinical research services are provided through a consulting agreement with GVI Clinical Development Solutions Inc. ("GVI CDS"), a company controlled by the Chief Executive Officer. Pharmacovigilance and safety, regulatory support, quality control and clinical support are provided to the Company through the GVI CDS agreement. During the year ended December 31, 2018, the Company paid GVI CDS $857,917 (2017 – $715,623; 2016 – $592,464) for clinical research services. Research and development services are provided through a consulting agreement with CanAm Bioresearch Inc. ("CanAm"), a company controlled by a close family member of the President and Chief Executive Officer. During the year ended December 31, 2018, the Company paid CanAm $393,021 (2017 – $458,424; 2016 – $560,205) for research and development services. Beginning with the acquisition of Apicore (the “Acquisition”) on December 1, 2016 and ending with the Apicore Sales Transaction on October 2, 2017 (note 5), the Company incurred rental charges pertaining to leased manufacturing facilities and office space from Dap Dhaduk II LLC (“Dap Dhaduk”), an entity controlled by a minority shareholder and member of the board of directors of Apicore Inc. Included within discontinued operations on the consolidated statements of net income and comprehensive income is payments to Dap Dhaduk totaling $263,493 and $29,869 for the years ended December 31, 2017 and 2016, respectively. Beginning with the Acquisition on December 1, 2016 and ending with the Apicore Sales Transaction on October 2, 2017 (note 5), the Company purchased inventory from Aktinos Pharmaceuticals Private Limited and Aktinos HealthCare Private Limited (together, “Aktinos”), an entity significantly influenced by a close family member of the Chief Executive Officer of Apicore Inc. For the year ended December 31, 2017, the Company paid Aktinos $1,599,056 (2016 – $217,382) for purchases of inventory, which were included in assets of the Apicore business sold (note 5) in connection with the Apicore Sales Transaction. Beginning with the Acquisition on December 1, 2016 and ending with the Apicore Sales Transaction on October 2, 2017 (note 5), the Company incurred research and development charges from Omgene Life Sciences Pvt. Ltd. (“Omgene”), an entity significantly influenced by a close family member of the Chief Executive Officer of Apicore Inc. Included within discontinued operations on the consolidated statements of net income and comprehensive income is payments to Omgene totaling $26,465 and nil for the years ended December 31, 2017 and 2016, respectively. Beginning with the Acquisition on December 1, 2016 and ending with the Apicore Sales Transaction on October 2, 2017 (note 5), the Company incurred pharmacovigilance charges from 4C Pharma Solutions LLC (“4C Pharma”), an entity significantly influenced by a close family member of the Chief Executive Officer of Apicore Inc. Included within discontinued operations on the consolidated statements of net income and comprehensive income is payments to 4C Pharma totaling $5,690 and nil for the years ended December 31, 2017 and 2016, respectively. These transactions have been measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. As at December 31, 2018, included in accounts payable and accrued liabilities is $16,843 (2017 $67,704) payable to GVI, $134,461 (2017 $118,973) payable to GVI CDS, and $40,452 (2017 $36,606) payable to CanAm. These amounts are unsecured, payable Effective July 18, 2016, the Company renewed its consulting agreement with its Chief Executive Officer, through A.D. Friesen Enterprises Ltd., a company owned by the Chief Executive Officer, for a term of five years, at a rate of $300,000 annually, increasing to $315,000 annually, effective January 1, 2017. The Company may terminate this agreement at any time upon 120 days’ written notice. As at December 31, 2018, there were no amounts included in accounts payable and accrued liabilities (2017 – $125,000) payable to A.D. Friesen Enterprises Ltd. as a result of this consulting agreement. Any amounts payable to A.D. Friesen Enterprises Ltd. are unsecured, payable on demand and non-interest bearing. Effective January 1, 2018, the Company renewed its consulting agreement with its Chief Financial Officer, through JFK Enterprises Ltd., a company owned by the Chief Financial Officer of the Company, for a one-year term, at a rate of $155,000 annually. The agreement could have been terminated by either party, at any time, upon 30 days written notice. Any amounts payable to JFK Enterprises Ltd. were unsecured, payable on demand and non-interest bearing. Effective June 1, 2018, this consulting agreement was converted into an employment agreement with the Chief Financial Officer.

Expenses by nature

Expenses by nature	12 Months Ended
	Dec. 31, 2018
Expenses by nature [abstract]
Expenses by nature	17. Expenses by nature Expenses incurred for the years ended December 31, 2018, 2017 and 2016 from continuing operations are as follows: Year ended December 31 2018 2017 2016 Personnel expenses Salaries, fees and short-term benefits $ 7,696,387 $ 5,903,669 $ 5,804,883 Share-based payments 1,022,176 490,769 1,340,001 8,718,563 6,394,438 7,144,884 Amortization and derecognition 299,184 97,794 1,433,573 Research and development 5,306,468 3,538,547 2,270,964 Manufacturing 764,712 955,160 1,062,684 Inventory material costs 3,861,740 3,079,397 2,482,986 Write-down (write-up) of inventory 94,517 385,289 (108,817 ) Medical affairs 1,026,465 1,108,090 1,040,755 Administration 1,504,799 1,724,584 1,526,682 Selling and logistics 8,018,787 5,395,373 5,355,876 Professional fees 740,353 801,882 559,287 $ 30,335,588 $ 23,480,554 $ 22,768,874

Financial instruments

Financial instruments	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about financial instruments [abstract]
Financial instruments	18. Financial instruments (a) Financial assets and liabilities Set out below is a comparison by class of the carrying amounts and fair value of the Company's financial instruments as at December 31, 2018 and 2017: As at December 31 2018 2017 Carrying Fair Carrying Fair Financial assets Financial assets measured at amortized cost Cash and cash equivalents $ 24,139,281 $ 24,139,281 $ 5,260,480 $ 5,260,480 Short-term investments 47,747,000 47,747,000 - - Accounts receivable 10,764,579 10,764,579 8,588,255 8,588,255 Consideration receivable - - 82,678,366 82,678,366 Holdback receivable 11,909,368 11,909,368 12,068,773 12,068,773 Financial liabilities Financial liabilities measured at amortized cost: Accounts payable and accrued liabilities $ 14,378,215 $ 14,378,215 $ 10,371,103 $ 10,371,103 Accrued transaction costs - - 22,360,730 22,360,730 Current portion of royalty obligation 1,495,548 1,495,548 1,537,202 1,537,202 Royalty obligation 2,035,010 2,035,010 2,911,810 2,911,810 License fee payable - - 501,800 501,800 Other long-term liability 1,200,608 1,200,608 1,135,007 1,135,007 The Company has determined the estimated fair values of its financial instruments based on appropriate valuation methodologies. The carrying values of current monetary assets and liabilities approximate their fair values due to their relatively short periods to maturity. The royalty obligation, license fee payable and other long-term liability are carried at amortized cost. The holdback receivable is carried at FVTPL. IFRS 13, Fair Value Measurement • Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2 – Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; • Level 3 – Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. The fair value hierarchy of the following financial assets and liabilities on the consolidated statements of financial position as at December 31, 2018 is as follows: Level 1 Level 2 Level 3 Financial assets Holdback receivable $ - $ - $ 11,909,368 Financial liabilities Accounts payable and accrued liabilities $ - $ - $ 545,680 Current portion of royalty obligation - - 1,495,548 Royalty obligation - - 2,035,010 Other long-term liabilities - - 1,200,608 Included in accounts payable and accrued liabilities as at December 31, 2018 is the current portion of the license fee payable of $545,680. The fair value hierarchy of the following financial assets and liabilities on the consolidated statements of financial position as at December 31, 2017 is as follows: Level 1 Level 2 Level 3 Financial assets Assets held for sale $ - $ 14,052,861 $ - Holdback receivable - - 12,068,773 Financial liabilities Accounts payable and accrued liabilities $ - $ - $ 877,150 Current portion of royalty obligation - - 1,537,202 Liabilities held for sale - 6,976,313 - Royalty obligation - - 2,911,810 License fee payable - - 501,800 Other long-term liability - - 1,135,007 Included in accounts payable and accrued liabilities as at December 31, 2017 is the current portion of the license fee payable of $877,150. Royalty obligation: ® ® For assets and liabilities that are recognized in the consolidated financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period. During the years ended December 31, 2018, 2017 and 2016 there were no transfers between Level 1 and Level 2 fair value measurements. (b) Risks arising from financial instruments and risk management The Company's activities expose it to a variety of financial risks; market risk (including foreign exchange and interest rate risks), credit risk and liquidity risk. Risk management is the responsibility of the Company, which identifies, evaluates and, where appropriate, mitigates financial risks. (i) Market risk (a) The Company is exposed to U.S. dollar currency risk through the following U.S. denominated financial assets and liabilities: As at December 31 (Expressed in U.S. Dollars) 2018 2017 Cash $ 17,427,653 $ 4,086,080 Short-term investments 35,000,000 - Accounts receivable 7,725,228 6,792,664 Consideration receivable - 65,905,433 Holdback receivable 8,729,928 9,620,385 Accounts payable and accrued liabilities (9,902,571 ) (7,174,456 ) Accrued transaction costs - (17,824,416 ) Income taxes payable (775,903 ) (1,935,879 ) Current portion of royalty obligation (1,096,282 ) (1,225,350 ) Royalty obligation (1,491,724 ) (2,321,092 ) License fee payable - (400,000 ) Other long-term liability (880,082 ) (904,749 ) $ 54,736,247 $ 54,618,620 Based on the above net exposures as at December 31, 2018, assuming that all other variables remain constant, a 5% appreciation or deterioration of the Canadian dollar against the U.S. dollar would result in a corresponding increase or decrease, respectively on the Company's net income of approximately $3.7 million (2017 – $3.8 million). The Company is also exposed to currency risk on the Euro, however management estimates such risk relating to an appreciation or deterioration of the Canadian dollar against the Euro would have limited impact on the operations of the Company. (b) (ii) Credit risk Credit risk is the risk of financial loss to the Company if a partner or counterparty to a financial instrument fails to meet its contractual obligation and arises principally from the Company’s cash, accounts receivable, consideration receivable and holdback receivable. The carrying amounts of the financial assets represents the maximum credit exposure. The Company limits its exposure to credit risk on cash by placing these financial instruments with high-credit quality financial institutions. The Company is subject to a concentration of credit risk related to its accounts receivable as 96% of the balance of amounts owing are from three customers. The Company has historically had low impairment in regards to its accounts receivable. As at December 31, 2018, none of the outstanding accounts receivable were outside of the normal payment terms and the Company did not record any bad debt expenses (2017 – nil; 2016 – nil). (iii) Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company manages its liquidity risk by continuously monitoring forecasted and actual cash flows, as well as anticipated investing and financing activities and to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due and to fund future operations. The majority of the Company’s accounts payable and accrued liabilities are due within the current operating period. (c) Capital management The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to continue the business of the Company. The Company, upon approval from its Board of Directors, will balance its overall capital structure through new share and warrant issuances, granting of stock options, the issuance of debt or by undertaking other activities as deemed appropriate under the specific circumstance. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern and to provide capital to pursue the development and commercialization of its products. In the management of capital, the Company includes cash, long-term debt, capital stock, stock options, warrants and contributed surplus. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares or new debt. At the current stage of the Company's development, in order to maximize its current business activities, the Company does not pay out dividends. Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. The Company’s overall strategy with respect to capital risk management remains unchanged for the year ended December 31, 2018.

Determination of fair values

Determination of fair values	12 Months Ended
	Dec. 31, 2018
Disclosure Of Fair Value Measurement Explanatory [Abstract]
Determination of fair values	19. Determination of fair values A number of the Company's accounting policies and disclosures require the determination of fair value, for both financial and non-financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following models. When applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that asset or liability. (a) Intangible assets The fair value of intangible assets is based on the discounted cash flows expected to be derived from the use and eventual sale of the assets. (b) Share-based payment transactions The fair value of the employee share options is measured using the Black-Scholes option pricing model. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historical volatility adjusted for changes expected due to publicly available information), weighted average expected life of the instruments (based on historical experience and general option holder behavior), expected dividends, and the risk-free interest rate (based on government bonds). Service and non-market performance conditions attached to the transactions are not taken into account in determining fair value. (c) Royalty obligation The royalty obligation is recorded at its fair value at the date at which the liability was incurred and subsequently measured at amortized cost using the effective interest rate method at each reporting date. Estimating fair value for this liability requires determining the most appropriate valuation model which is dependent on its underlying terms and conditions. This estimate also requires determining expected revenue from AGGRASTAT ® (d) Holdback receivable The holdback receivable is recorded at its fair value at the date at the date of acquisition and subsequently measured at fair value at each reporting date. Estimating fair value for this asset requires determining the most appropriate valuation model which is dependent on its underlying terms and conditions. This estimate also requires determining expected cash flows from this receivable including potential claims from the Buyer in the Apicore Sales Transaction (Note 10) and an appropriate discount rate and making assumptions about them.

Segmented information

Segmented information	12 Months Ended
	Dec. 31, 2018
Disclosure of operating segments [abstract]
Segmented information	20. Segmented information Prior to October 2, 2017, the operations of the Company were classified into two industry segments: the marking and distribution of commercial products (AGGRASTAT®) and the manufacturing and distribution of API, which was classified as held for sale and discontinued operations in 2017 (note 5). No operating segments were aggregated to form these reportable operating segments. Since the sale of API on October 2, 2017, the Company operates under one segment. Revenue generated from external customers from the marketing and distribution of commercial products (AGGRASTAT ® During the year ended December 31, 2018, 100% of total revenue was generated from eight customers. Customer A accounted for 33%, Customer B accounted for 28%, Customer C accounted for 33% and Customer D accounted for 6% and the remaining five customers accounted for less than 1% of revenue. During the year ended December 31, 2017, 99% of total revenue was generated from nine customers. Customer A accounted for 33%, Customer B accounted for 30%, Customer C accounted for 30% and Customer D accounted for 6% and the remaining five customers accounted for less than 1% of revenue. During the year ended December 31, 2016, 100% of total revenue was generated from nine customers. Customer A accounted for 36%, Customer B accounted for 32%, Customer C accounted for 20% and Customer D accounted for 11% and the remaining five customers accounted for less than 1% of revenue. Property, plant and equipment and intangible assets are located in the following countries: As at December 31 2018 2017 Canada $ 316,013 $ 218,488 Barbados 1,705,250 1,756,300 United States - 3,134 $ 2,021,263 $ 1,977,922

Subsequent events

Subsequent events	12 Months Ended
	Dec. 31, 2018
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent events	21. Subsequent events Subsequent to December 31, 2018, on January 28, 2019, the Company entered into an agreement with Sensible Medical Innovations Inc. (“Sensible”) to become the exclusive marketing partner for the ReDS™ point of care system (“ReDS”) in the United States. ReDS is a non-invasive, FDA-cleared medical device that provides an accurate, actionable and absolute measurement of lung fluid which is important in the management of congestive heart failure. Under the terms of the agreement, Medicure will receive a percentage of total U.S. sales revenue of the device and must meet minimum annual sales quotas. In addition, Medicure has invested US$10.0 million in Sensible for a 7.71% equity stake on a fully diluted basis.

Significant accounting polici_2

Significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Basis of consolidation	(a) Basis of consolidation These consolidated financial statements include the accounts of the Company and its subsidiaries. Subsidiaries are entities controlled by the Company. Control exists when the Company has power over the investee and when the Company is exposed, or has the rights, to variable returns from the investee. Subsidiaries are included in the consolidated financial results of the Company from the effective date of acquisition up to the effective date of disposition or loss of control and include wholly owned subsidiaries, Medicure International Inc., Medicure Pharma Inc., Medicure U.S.A. Inc., Medicure Mauritius Limited, Medicure Pharma Europe Limited and Apigen Investments Limited. Additionally, the December 31, 2016 comparative figures include,
Foreign currency	(b) Foreign currency Items included in the financial statements of each of the Company's consolidated subsidiaries are measured using the currency of the primary economic environment in which the subsidiary operates (the functional currency). The consolidated financial statements are presented in Canadian dollars, which is the Company's functional and presentation currency. Foreign currency transactions are translated into the respective functional currencies of the Company and its subsidiaries using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Non-monetary items that are not carried at fair value are translated using the exchange rates as at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. The results and financial position of the Company's foreign operations that have a functional currency different from the Company’s functional and presentation currency are translated into Canadian dollars as follows: (i) (ii) (iii) When a foreign operation is disposed of, the component of other comprehensive income relating to that particular foreign operation is recognized in the consolidated statements of net income and comprehensive income, as part of the gain or loss on sale where applicable.
Financial instruments	(c) Financial instruments (i) Financial assets The Company initially recognizes a financial asset on the trade date at which the Company becomes a party to the contractual provisions of the instrument. Upon recognition of a financial asset, classification is made based on the business model for managing the asset and the asset’s contractual cash flow characteristics. The financial asset is initially recognized at its fair value and subsequently measured as (i) amortized cost; (ii) fair value through other comprehensive income (“ FVOCI FVTPL The Company derecognizes a financial asset when the contractual cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. Financial assets and liabilities are offset and the net amount presented in the consolidated statements of financial position when, and only when, the Company has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. The Company has classified all of its non-derivative financial assets as financial assets measured at amortized cost, except for the consideration receivable and the holdback receivable, which are classified as FVTPL. The Company has not classified any financial assets as FVOCI. Financial assets measured at amortized cost A non-derivative financial asset is measured at amortized cost when both of the following conditions are met: (i) the asset is held within a business model whose objective is to hold assets in order to collect the contractual cash flows; and (ii) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Such assets are recognized initially at fair value plus any directly attributable transaction costs and measured at amortized cost using the effective interest method subsequent to initial recognition. Financial assets measured at amortized cost are cash and cash equivalents, short-term investments and accounts receivable (ii) Financial liabilities All financial liabilities are recognized initially on the trade date at which the Company becomes a party to the contractual provisions of the instrument. Such financial liabilities are recognized initially at fair value plus any directly attributable transaction costs. All financial liabilities are measured at amortized cost, except for any financial liabilities measured at FVTPL. A financial liability may no longer be reclassified subsequent to initial recognition. Subsequent to initial recognition, financial liabilities are measured at amortized cost using the effective interest method. The Company decognizes a financial liability when its contractual obligations are discharged, cancelled or when they expire. The royalty obligation was recorded at its fair value at the date at which the liability was incurred and subsequently measured at amortized cost using the effective interest rate method at each reporting date. Estimating fair value for this liability required determining the most appropriate valuation model which was dependent on its underlying terms and conditions. This estimate also required determining expected revenue from AGGRASTAT ®
Impairment of financial assets	(d) Impairment of financial assets Impairment of financial assets is recognized in accordance with a stage-based approach. The first stage begins upon recognition of a financial asset upon which time a loss allowance is recorded and 12-month expected credit losses are recognized in profit or loss. A financial asset is in the second stage of impairment when the credit risk increases significantly and is not considered low upon which time full lifetime expected credit losses are recorded in profit or loss. A financial asset is in the third stage of impairment when the credit risk increases to the point that it is credit impaired. Applicable interest revenue is calculated on the gross carrying amount of financial assets that are in the first or second stage of impairment and on the amortized carrying amount of a financial asset of a financial asset in the third stage of impairment. Impairment losses on financial assets carried at amortized cost are reversed in subsequent periods if the amount of the loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized.
Revenue from contracts with customers	(e) Revenue from contracts with customers The Company has two commercially available products, AGGRASTAT® and ZYPITAMAG™ (the “ Products Sales are made subject to certain discounts available for prompt payment, volume discounts, rebates or chargebacks. Revenue from these sales is recognized based on the price specified per the pricing terms of the sales invoices, net of the estimated discounts. Variable consideration is based on historical information, using the expected value method. Revenue is only recognized to the extent that it is highly probable that a significant reversal will not occur. A liability is included within accounts payable and accrued liabilities and is measured for expected payments that will be made to the customers for the discounts in which they are entitled. Sales do not contain an element of financing as sales are made with a credit terms within the normal operating cycle of the date of the invoice, which is consistent with market practice.
Cash and cash equivalents	(f) Cash and cash equivalents The Company considers all liquid investments purchased with a maturity of three months or less at acquisition to be cash and cash equivalents, which are carried at amortized cost and are classified at amortized cost.
Short-term investments	(g) Short-term investments The Company considers all liquid investments purchased with a maturity greater than three months and less than one year at acquisition to be short-term investments, which are carried and classified at amortized cost.
Inventories	(h) Inventories Inventories consist of unfinished product (raw material in the form of API and packaging materials) and finished The cost of inventories is based on the first-in first-out principle, and includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. When the circumstances that previously caused inventories to be written down below cost no longer exist, or when there is clear evidence of an increase in selling prices, the amount of the write-down previously recorded is reversed.
Property plant and equipment	(i) Property plant and equipment (i) Recognition and measurement Items of property, plant and equipment are measured at cost less accumulated amortization and accumulated impairment losses and reversals. When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. The costs of the day-to-day servicing of property, plant and equipment are recognized in the consolidated statements of net income and comprehensive income in the period in which they are incurred. (ii) Amortization Amortization is recognized in profit or loss over the estimated useful lives of each part of an item of property, plant and equipment in a manner that most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are as follows: Asset Basis Rate Computers, office equipment, furniture and fixtures Straight-line/Diminishing balance 20% to 25% Leasehold improvements Straight-line Term of lease Amortization methods, useful lives and residual values are reviewed at each period end and adjusted if appropriate.
Leases	(j) Leases The determination of whether an arrangement is a lease is based on the substance of the arrangement at the inception of the lease. The arrangement is, or contains, a lease if fulfillment of the arrangement is dependent on the use of specific assets and the arrangement conveys a right to use the assets, even if those assets are not explicitly specified in an arrangement. A lease is classified at inception date as a finance or operating lease. A lease that transfers substantially all the risks and rewards incidental to ownership to the Company is classified as a finance lease. Finance leases are capitalized at the commencement of the lease at the inception date fair value of the leased property or, if lower, at the present value of the minimum lease payments. Lease payments are apportioned between finance expense and reduction of the lease liability so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are recognized in finance costs in the consolidated statements of net income and comprehensive income. Leased assets are depreciated over the useful life of each asset. However, if there is no reasonable certainty that the Company will obtain ownership by the end of the lease term, the asset is depreciated over the shorter of the estimated useful life of the asset and the lease term. An operating lease is a lease other than a finance lease. Operating lease payments are recognized as an operating expense in the consolidated statements of net income and comprehensive income on a straight-line basis over the lease term.
Intangible assets	(k) Intangible assets Intangible assets that are acquired separately are measured at cost less accumulated amortization and accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred. Licenses are amortized on a straight-line basis over the contractual term of the acquired license. Patents are amortized on a straight-line basis over the legal life of the respective patent, ranging from five to twenty years, or its economic life, if shorter. Trademarks are amortized on a straight-line basis over the legal life of the respective trademark, being ten years, or its economic life, if shorter. Customer lists are amortized on a straight-line basis over approximately twelve years, or its economic Amortization on licenses commences when the intangible asset is available for use, which would typically be in connection with the commercial launch of the associated product under the license. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses. The cost of servicing the Company's patents and trademarks are expensed as incurred. The amortization method and amortization period of an intangible asset with a finite useful life are reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates in the consolidated statements of net income and comprehensive income.
Research and development	(l) Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss as incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. No development costs have been capitalized to date. Research and development expenses include all direct and indirect operating expenses supporting the products in development. Clinical trial expenses are a component of the Company’s research and development costs. These expenses include fees paid to contract research organizations, clinical sites, and other organizations who conduct research and development activities on the Company’s behalf. The amount of clinical trial expenses recognized in a period related to clinical agreements are based on estimates of the work performed using an accrual basis of accounting. These estimates incorporate factors such as patient enrolment, services provided, contractual terms, and prior experience with similar contracts.
Government assistance	(m) Government assistance Government assistance, in the form of grants, is recognized at fair value where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. Government assistance toward current expenses is recorded as a reduction of the related expenses in the period the expenses are incurred. Government assistance towards property, plant and equipment is deducted from the cost of the related property, plant and equipment. The benefits of investment tax credits for scientific research and experimental development expenditures ("SR&ED") incurred directly by the Company are recognized in the period the qualifying expenditure is made, provided there is reasonable assurance of recoverability. SR&ED investment tax credits receivable are recorded at their net realizable value.
Impairment of non-financial assets	(n) Impairment of non-financial assets The Company assesses at each reporting period whether there is an indication that a non-financial asset may be impaired. An impairment loss is recognized when the carrying amount of an asset, or its CGU, exceeds its recoverable amount. Impairment losses are recognized in net income and comprehensive income. A CGU is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets. The recoverable amount is the greater of the asset's or CGU's fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU. In determining fair value less costs to sell, an appropriate valuation model is used. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the CGU to which the asset belongs. For assets other than goodwill, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of amortization, if no impairment loss had been recognized. Goodwill is tested for impairment annually and when circumstances indicate that the carrying value may be impaired. Impairment is determined for goodwill by assessing the recoverable amount of each CGU to which the goodwill relates. When the recoverable amount of the CGU is less than its carrying amount, an impairment loss is recognized. Impairment losses relating to goodwill are not reversed in future periods.
Employee benefits	(o) Employee benefits (i) Short-term employee benefits Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. (ii) Share-based payment transactions The grant date fair value of share-based payment awards granted to employees is recognized as a personnel expense, with a corresponding increase in equity, over the period that the employees unconditionally become entitled to the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant date fair value of the share-based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcomes. Share-based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity-settled share-based payment transactions. In situations where equity instruments are issued and some or all of the goods or services received by the entity as consideration cannot be specifically identified, they are measured at fair value of the share-based payment. For share-based payment arrangements with non-employees, the expense is recorded over the service period until the options vest. Once the options vest, services are deemed to have been received. Where the terms of an equity-settled transaction award are modified, the minimum expense recognized is the expense as if the terms had not been modified, if the original terms of the award are met. An additional expense is recognized for any modification that increases the total fair value of the share-based payment transaction or is otherwise beneficial to the employee as measured at the date of modification. Where an equity-settled award is cancelled, it is treated as if it vested on the date of the cancellation and any expense not yet recognized for the award [being the total expense as calculated at the grant date] is recognized immediately. This includes any awards where vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award, and designated as a replacement award on the date that it is granted, the cancelled award and new awards are treated as if they were a modification of the original awards.
Finance income and finance costs	(p) Finance income and finance costs Finance costs comprise interest expense on borrowings which are recognized in net income and comprehensive income using the effective interest rate method, accretion on the royalty obligation, prepayment fees on the early repayment of long-term debt and amortization of deferred debt issue costs using the effective interest rate method, offset by any finance income which is comprised of interest income on funds invested and is recognized as it accrues in net income and comprehensive income, using the effective interest rate method. Foreign currency gains and losses are reported on a net basis.
Income taxes	(q) Income taxes The Company and its subsidiaries are generally taxable under the statutes of their country of incorporation. Income tax expense comprises current and deferred taxes. Current taxes and deferred taxes are recognized in profit or loss except to the extent that they relate to a business combination, or items recognized directly in equity or in other comprehensive income. Current taxes are the expected tax receivable or payable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax receivable or payable in respect of previous years. The Company follows the liability method of accounting for deferred taxes. Under this method, deferred taxes are recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred taxes are not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss, and differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future. In addition, deferred taxes are not recognized for taxable temporary differences arising on the initial recognition of goodwill. Deferred taxes are measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the tax laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax assets and liabilities, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax assets and liabilities on a net basis or their tax assets and liabilities will be realized simultaneously. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. The Company has provided for income taxes, including the impacts of tax legislation in various jurisdictions, in accordance with guidance issued by accounting regulatory bodies, the Canada Revenue Agency, the U.S. Internal Revenue Service, the Barbados Revenue Authority, the Mauritius Revenue Authority, as well as other state and local governments through the date of the issuance of these consolidated financial statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results. While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time. The Company and its subsidiaries file federal income tax returns in Canada, the United States, Barbados and other foreign jurisdictions, as well as various provinces and states in Canada and the United States. The Company and its subsidiaries have open tax years, primarily from 2009 to 2018, with significant taxing jurisdictions, including Canada, the United States and Barbados. These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years may remain open indefinitely. Tax benefits acquired as part of a business combination, but not satisfying the criteria for separate recognition at that date, would be recognized subsequently if information about facts and circumstances changed. The adjustment would either be treated as a reduction to goodwill if it occurred during the measurement period or in profit or loss, when it occurs subsequent to the measurement period.
Earnings per share	(r) Earnings per share The Company presents basic earnings per share ("EPS") data for its common voting shares. Basic EPS is calculated by dividing the profit or loss attributable to common voting shareholders of the Company by the weighted average number of common voting shares outstanding during the period, adjusted for the Company's own shares held. Diluted EPS is computed similar to basic EPS except that the weighted average shares outstanding are increased to include additional shares for the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options and warrants were exercised and that the proceeds from such exercise were used to acquire common shares at the average market price during the reporting periods.
Business combinations and goodwill	(s) Business combinations and goodwill Business combinations are accounted for using the acquisition method. The consideration for an acquisition is measured at the fair values of the assets transferred, the liabilities assumed and the equity interests issued at the acquisition date. Transaction costs that are incurred in connection with a business combination, other than costs associated with the issuance of debt or equity securities, are expensed as incurred. Identified assets acquired and liabilities and contingent liabilities assumed are measured initially at fair values at the date of acquisition. On an acquisition-by-acquisition basis, any non-controlling interest is measured either at fair value of the non-controlling interest or at the fair value of the proportionate share of the net assets acquired. Contingent consideration is measured at fair value on acquisition date and is included as part of the consideration transferred. The fair value of the contingent consideration liability is remeasured at each reporting date with the corresponding gain or loss being recognized in profit or loss. Goodwill is initially measured at cost, being the excess of fair value of the cost of the business combinations over the Company’s share in the net fair value of the acquiree’s identifiable assets, liabilities and contingent liabilities. Any negative difference is recognized directly in the consolidated statements of net income and comprehensive income. If the fair values of the assets, liabilities and contingent liabilities can only be calculated on a provisional basis, the business combination is recognized using provisional values. Any adjustments resulting from the completion of the measurement process are recognized within twelve months of the date of the acquisition.
New standards and interpretations	New standards and interpretations The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective. Set out below is the impact of the mandatory adoption of new standards: IFRS 9, Financial Instruments: Classification and Measurement Effective January 1, 2018, the Company has adopted IFRS 9 retrospectively. Prior periods were not restated and no material changes resulted from adoption of this new standard. IFRS 9 introduced a revised model for classification and measurement, which has resulted in several financial instrument reclassification changes by the Company. There were no quantitative impacts from adoption of IFRS 9. Upon recognition of a financial asset, classification is made based on the business model for managing the asset and the asset’s contractual cash flow characteristics. The financial asset is initially recognized at its fair value and subsequently classified and measured as (i) amortized cost; (ii) fair value through other comprehensive income (“FVOCI”); or (iii) fair value through profit or loss (“FVTPL”). Financial assets are classified as FVTPL if they have not been classified as measured at amortized cost or FVOCI. Upon initial recognition of an equity instrument that is not held-for-trading, the Company may irrevocable designate the presentation of subsequent changes in the fair value of such equity instrument as FVTPL. The Company recognizes a financial liability on the trade date in which it becomes a party to the contractual provisions of the instrument at fair value plus any directly attributable costs. Financial liabilities are subsequently measured at amortized cost or FVTPL, and are not subsequently reclassified. An “expected credit loss” impairment model applies which requires a loss allowance to be recorded on financial assets measured at amortized cost based on their expected credit losses. An estimate is made to determine the present value of future cash flows associated with the asset, and if required, an impairment loss is recorded. The impairment loss reduces the carrying value of the impaired financial asset to the value of the estimated present value of the future cash flows associated with the asset, discounted at the financial asset’s original effective interest rate is recorded either directly or through the use of an allowance account and the resulting impairment loss is recorded in profit or loss. Below is a summary showing the classification and measurement bases for the Company’s financial instruments as a result of the adoption of IFRS on January 1, 2018 with a comparison to the previous classification under IAS 39: Financial instrument Classification under IAS 39 Classification under IFRS 9 Financial assets Cash and equivalents Loans and receivables Amortized cost Short-term investments Loans and receivables Amortized cost Accounts receivable Loans and receivables Amortized cost Consideration receivable Loans and receivables Amortized cost Holdback receivable Loans and receivables Amortized cost Financial liabilities Accounts payable and accrued liabilities Other financial liabilities Amortized cost Accrued transaction costs Other financial liabilities Amortized cost Income taxes payable Other financial liabilities Amortized cost Current portion of royalty obligation Other financial liabilities Amortized cost Royalty obligation Other financial liabilities Amortized cost License fee payable Other financial liabilities Amortized cost Other long-term liability Other financial liabilities Amortized cost IFRS 15, Revenue from Contracts with Customers Effective January 1, 2018, the Company has adopted IFRS 15 retrospectively. Prior periods were not restated and no material changes resulted from adoption of this new standard. IFRS 15 and provides a model for the recognition and measurement of gains or losses from sales of some non-financial assets. The core principle is that revenue is recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The adoption of the standard will also result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and improve guidance for multiple-element arrangements. There were no quantitative impacts from adoption of IFRS 15. IFRS 2, Share-based Payments Effective January 1, 2018, the Company has adopted the required amendments to IFRS 2, which provides requirements on the accounting for the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments, share-based payment transactions with a net settlement feature for withholding tax obligations, and a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity settled. There were no quantitative impacts from adoption of the amendments to IFRS 2. New standards not yet adopted As at , the following standard has been issued but is not yet effective: IFRS 16, Leases In January 2016, the IASB issued IFRS 16 which requires lessees to recognize assets and liabilities for most leases. Lessees will have a single accounting model for all leases, with certain exemptions. The new standard is effective January 1, 2019, with limited early application permitted. The new standard permits lessees to use either a full retrospective or a modified retrospective approach on transition for leases existing at the date of transition, with options to use certain transition reliefs. The Company is currently evaluating the impact of the above amendments on its condensed consolidated interim financial statements.

Significant accounting polici_3

Significant accounting policies (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Schedule of estimated useful lives of property, plant and equipment	Asset Basis Rate Computers, office equipment, furniture and fixtures Straight-line/Diminishing balance 20% to 25% Leasehold improvements Straight-line Term of lease

Discontinued operations (Tables

Discontinued operations (Tables)	12 Months Ended
	Dec. 31, 2018
Discontinued Operations [Abstract]
Schedule of financial performance relating to the Apicore business	Year ended December 31 2018 2017 2016 Revenue $ - $ 22,759,385 $ 7,798,838 Expenses - (47,936,485 ) (9,263,926 ) Revaluation of long-term derivative - - 20,560,440 Gain on step acquisition - - 4,895,573 (Loss) income from discontinued operations $ - $ (25,177,100 ) $ 23,990,925 Income tax recovery (expense) - 1,847,055 (632,607 ) Loss (income) after income tax recovery (expense) $ - (23,330,045 ) 23,358,318 Gain on disposition of the Apicore business - 55,254,236 - Income from discontinued operations $ - $ 31,924,191 $ 23,358,318
Schedule of cash flow information of Apicore business	Year ended December 31 2018 2017 2016 Net cash flows used in operating activities $ - $ 5,210,341 $ (1,295,487 ) Net cash flows from (used in) investing activities - 54,326,360 (421,077 ) Net cash flows from (used in) financing activities - (80,944,373 ) 44,294,204 Net cash flows used in discontinued operations $ - $ (21,407,672 ) $ 42,577,640

Accounts receivable (Tables)

Accounts receivable (Tables)	12 Months Ended
	Dec. 31, 2018
Trade and other receivables [abstract]
Schedule of accounts receivable	As at December 31 2018 2017 Trade accounts receivable $ 9,677,847 $ 8,496,281 Other accounts receivable 1,086,732 91,974 $ 10,764,579 $ 8,588,255

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Inventories [Abstract]
Schedule of inventories	As at December 31 2018 2017 Finished product available-for-sale $ 2,936,883 $ 2,058,776 Unfinished product and packaging materials 1,302,384 1,016,230 $ 4,239,267 $ 3,075,006

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about property, plant and equipment [abstract]
Schedule of property, plant and equipment	Cost Land Building Computer Machinery Leasehold Total At December 31, 2016 $ 2,316,979 $ 2,122,687 $ 2,439,071 $ 2,798,482 $ 1,003,490 $ 10,680,709 Additions - 82,163 675,788 298,754 - 1,056,705 Transfers to assets held for resale (2,317,273 ) (2,900,284 ) (3,319,298 ) (4,572,065 ) (790,814 ) (13,899,734 ) Effect of movements in exchange rates 294 695,434 632,604 1,474,829 (56,333 ) 2,746,828 At December 31, 2017 $ - $ - $ 428,165 $ - $ 156,343 $ 584,508 Additions - - 185,682 - 11,812 197,494 Effect of movements in exchange rates - - 12,078 - - 12,078 Dispositions - - (156,280 ) - - (156,280 ) At December 31, 2018 $ - $ - $ 469,645 $ - $ 168,155 $ 637,800 Accumulated amortization and impairment losses Land Building Computer Machinery Leasehold Total At December 31, 2016 $ - $ 21,408 $ 250,261 $ 67,541 $ 40,860 $ 380,070 Amortization - 291,638 339,358 384,486 157,537 1,173,019 Transfers to assets held for resale - (306,761 ) (286,632 ) (443,746 ) (112,213 ) (1,149,352 ) Effect of movements in exchange rates - (6,285 ) (21,720 ) (8,281 ) (4,565 ) (40,851 ) At December 31, 2017 $ - $ - $ 281,267 $ - $ 81,619 $ 362,886 Amortization - - 75,471 - 27,736 103,207 Effect of movements in exchange rates - - 11,974 - - 11,974 Dispositions - - (156,280 ) - - (156,280 ) At December 31, 2018 $ - $ - $ 212,432 $ - $ 109,355 $ 321,787 Carrying amounts Land Building Computer Machinery Leasehold Total At December 31, 2017 $ - $ - $ 146,898 $ - $ 74,724 $ 221,622 At December 31, 2018 $ - $ - $ 257,213 $ - $ 58,800 $ 316,013

Intangible assets (Tables)

Intangible assets (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about intangible assets [abstract]
Schedule of intangible assets	Cost Licenses Patents Trademarks Customer Approved Acquired in Total At December 31, 2016 $ - $ 25,012,530 $ 4,296,192 $ 7,472,143 $ 1,505,664 $ 83,720,025 $ 122,006,554 Additions 2,383,550 - - - - - 2,383,550 Impairment (635,721 ) - - - - - (635,721 ) Transfers to assets held for resale - (9,122,874 ) - (6,267,525 ) (1,405,541 ) (78,152,819 ) (94,948,759 ) Effect of movements in exchange rates 8,471 (1,650,944 ) (282,211 ) (496,269 ) (100,123 ) (5,567,206 ) (8,088,282 ) At December 31, 2017 $ 1,756,300 $ 14,238,712 $ 4,013,981 $ 708,349 $ - $ - $ 20,717,342 Effect of movements in exchange rates 153,580 1,245,105 351,004 61,943 - - 1,811,632 At December 31, 2018 $ 1,909,880 $ 15,483,817 $ 4,364,985 $ 770,292 $ - $ - $ 22,528,974 Accumulated Licenses Patents Trademarks Customer Approved Acquired in Total At December 31, 2016 $ - $ 15,321,230 $ 4,296,192 $ 814,101 $ 12,548 $ 697,666 $ 21,141,737 Amortization - 637,406 - 437,904 98,203 5,460,444 6,633,957 Transfers to assets held for resale - (684,216 ) - (470,064 ) (105,416 ) (5,861,461 ) (7,121,157 ) Effect of movements in exchange rates - (1,035,708 ) (282,211 ) (73,592 ) (5,335 ) (296,649 ) (1,693,495 ) At December 31, 2017 $ - $ 14,238,712 $ 4,013,981 $ 708,349 $ - $ - $ 18,961,042 Amortization 195,977 - - - - - 195,977 Effect of movements in exchange rates 8,653 1,245,105 351,004 61,943 - - 1,666,705 At December 31, 2018 $ 204,630 $ 15,483,817 $ 4,364,985 $ 770,292 $ - $ - $ 20,823,724 Carrying amounts Licenses Patents Trademarks Customer Approved Acquired in Total At December 31, 2017 $ 1,756,300 $ - $ - $ - $ - $ - $ 1,756,300 At December 31, 2018 $ 1,705,250 $ - $ - $ - $ - $ - $ 1,705,250

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Capital Stock [Abstract]
Schedule of shares issued and outstanding	Number of Common Shares Amount Balance, December 31, 2016 15,532,408 $ 124,700,345 Shares issued upon exercise of stock options (12(c)) 207,950 869,703 Shares issued upon exercise of warrants (12(d)) 41,969 163,679 Balance, December 31, 2017 15,782,327 $ 125,733,727 Shares issued upon exercise of stock options (12(c)) 206,885 654,711 Shares repurchased and cancelled under a normal course issuer bid (*) (441,400 ) (3,501,333 ) Balance, December 31, 2018 15,547,812 $ 122,887,105 (*)
Schedule of changes in stock options	Year ended December 31, 2018 Options Weighted Balance, beginning of period 1,602,127 $ 3.58 Granted 200,000 7.25 Exercised (206,885 ) (1.76 ) Forfeited, cancelled or expired (200,600 ) (6.85 ) Balance, end of period 1,394,642 $ 3.91 Options exercisable, end of period 1,044,892 $ 2.80 Year ended December 31 2017 2016 Options Weighted Options Weighted Balance, beginning of period 1,387,000 $ 2.37 2,277,126 $ 1.90 Granted 476,000 7.20 265,025 6.16 Exercised (207,950 ) (2.50 ) (1,069,434 ) (1.72 ) Forfeited, cancelled or expired (52,923 ) (8.58 ) (85,717 ) (9.59 ) Balance, end of period 1,602,127 $ 3.58 1,387,000 $ 2.37 Options exercisable, end of period 1,231,127 $ 2.50 1,387,000 $ 2.37
Schedule of contractual life of options outstanding	Range of Number Weighted Options outstanding Number $0.30 185,000 4.35 years $ 0.30 185,000 $0.31 - $1.00 5,334 0.29 years $ 0.60 5,334 $1.01 - $3.00 549,433 3.35 years $ 1.59 549,433 $3.01 - $5.00 32,500 1.90 years $ 3.90 32,500 $5.01 - $7.30 622,375 3.89 years $ 7.06 272,625 $0.30 - $7.30 1,394,642 3.68 years $ 3.91 1,044,892
Schedule of fair value of the options using the Black-Scholes option pricing model	Years ended December 31: 2018 2017 2016 Expected option life 4.4 years 4.5 years 4.8–5.0 years Risk free interest rate 1.92%-2.04% 1.71 % 0.52%-0.67% Dividend yield Nil nil nil Expected volatility 85.14%-93.72% 80.44 % 115.59%-117.56%
Schedule of changes in warrants outstanding	Years ended December 31 2018 2017 2016 Warrants Weighted Warrants Weighted Warrants Weighted Balance, beginning of period 900,000 $ 6.50 941,969 $ 6.31 59,775 $ 2.20 Granted - - - - 900,000 6.50 Exercised - - (41,969 ) (2.20 ) (17,806 ) (2.20 ) Balance, end of period 900,000 $ 6.50 900,000 $ 6.50 941,969 $ 6.31 Warrants exercisable, end of period 900,000 $ 6.50 900,000 $ 6.50 941,969 $ 6.31
Schedule of fair value of the warrants issued using Black-Scholes pricing model	Years ended December 31 2016 Expected option life 4.0 years Risk-free interest rate 0.85 % Dividend yield nil Expected volatility 120.40 %
Schedule of calculation of basic and diluted earnings per share	Year ended December 31 2018 2017 2016 Net earnings before discontinued operations $ 0.25 $ 0.74 $ 0.24 Earnings from discontinued operations, net of tax - 2.04 1.56 $ 0.25 $ 2.78 $ 1.80 Year ended December 31 2018 2017 2016 Net earnings before discontinued operations $ 0.24 $ 0.63 $ 0.21 Earnings from discontinued operations, net of tax - 1.76 1.35 $ 0.24 $ 2.39 $ 1.56
Schedule of basic and diluted earnings per share	Year ended December 31 2018 2017 2016 Net earnings before discontinued operations $ 3,925,639 $ 11,496,693 $ 3,624,323 Earnings from discontinued operations, net of tax - 31,924,191 23,358,318 $ 3,925,639 $ 43,420,884 $ 26,982,641 Year ended December 31 2018 2017 2016 Weighted average shares outstanding for basic earnings per share 15,791,396 15,636,853 15,002,005 Effects of dilution from: Stock options 772,267 1,601,227 1,372,427 Warrants - 900,000 941,969 Weighted average shares outstanding for diluted earnings per share 16,563,663 18,138,080 17,316,401

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Taxes [Abstract]
Schedule of deferred tax assets and liabilities	As at December 31 2018 2017 Deferred tax assets Non-capital loss carryforwards $ 127,176 $ 326,108 Total deferred tax assets $ 127,176 $ 326,108
Schedule of deferred tax assets not recognized	As at December 31 2018 2017 Deferred tax assets Scientific research and experimental development $ 3,237,000 $ 3,574,000 Holdback receivable 199,000 - Other 159,000 315,000 Total deferred tax assets $ 3,595,000 $ 3,889,000
Schedule of reconciliation of statutory rate to the income tax rate applied to the net (loss) income	Year ended December 31 2018 2017 2016 Income (loss) for the year Canadian $ 3,439,883 $ (2,178,334 ) $ (4,012,706 ) Foreign 1,382,632 4,615,378 7,807,249 $ 4,822,515 $ 2,437,044 $ 3,794,543 Year ended December 31 2018 2017 2016 Canadian federal and provincial income taxes at 27% (2017 – 27%; 2016 – 27%) $ (1,302,000 ) $ (658,000 ) $ (1,025,000 ) Permanent differences and other items 26,000 (335,000 ) (758,000 ) Foreign tax rate in foreign jurisdictions 85,000 656,000 2,159,000 Change in unrecognized deferred tax assets 294,000 9,397,000 (546,000 ) $ (897,000 ) $ 9,060,000 $ (170,000 )
Schedule of barbados losses available for application in future years	2019 $ 2,478,000 2020 1,271,000 2022 1,339,000 $ 5,088,000

Finance income (expense) (Table

Finance income (expense) (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Finance Cost Income [Abstract]
Schedule of company's incurred finance income (expense)	Year ended December 31 2018 2017 2016 Interest income $ 1,114,676 $ 47,447 $ 30,452 Accretion of royalty obligation (355,287 ) (747,540 ) (2,271,436 ) Accretion on holdback receivable 325,522 - - Interest on MIOP loan - (105,670 ) (218,867 ) Bank charges and other interest (23,979 ) (31,698 ) (20,224 ) Change in fair value of warrant liability - - 1,161 $ 1,060,932 $ (837,461 ) $ (2,478,914 )
Schedule of company's paid finance income (expense)	Year ended December 31 2018 2017 2016 Interest received $ 279,098 $ 47,447 $ 30,452 Interest paid on MIOP loan - (88,828 ) (186,467 ) Other interest, net and banking fees (23,979 ) (31,698 ) (20,224 ) $ 255,119 $ 73,079 $ 176,239

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Commitment And Contingencies [Abstract]
Schedule of commitments and contingencies	2019 $ 4,005,841 2020 2,240,096 2021 1,274,935 2022 1,294,288 2023 204,630 Thereafter 204,630 $ 9,224,420

Related party transactions (Tab

Related party transactions (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of transactions between related parties [abstract]
Schedule of compensation paid to key management personnel	Year ended December 31 2018 2017 2016 Salaries, fees and short-term benefits $ 769,636 $ 1,463,106 $ 839,735 Termination benefits - - 221,624 Share-based payments 669,371 139,189 145,398 $ 1,439,007 $ 1,602,295 $ 1,206,757

Expenses by nature (Tables)

Expenses by nature (Tables)	12 Months Ended
	Dec. 31, 2018
Expenses by nature [abstract]
Schedule of expenses incurred	Year ended December 31 2018 2017 2016 Personnel expenses Salaries, fees and short-term benefits $ 7,696,387 $ 5,903,669 $ 5,804,883 Share-based payments 1,022,176 490,769 1,340,001 8,718,563 6,394,438 7,144,884 Amortization and derecognition 299,184 97,794 1,433,573 Research and development 5,306,468 3,538,547 2,270,964 Manufacturing 764,712 955,160 1,062,684 Inventory material costs 3,861,740 3,079,397 2,482,986 Write-down (write-up) of inventory 94,517 385,289 (108,817 ) Medical affairs 1,026,465 1,108,090 1,040,755 Administration 1,504,799 1,724,584 1,526,682 Selling and logistics 8,018,787 5,395,373 5,355,876 Professional fees 740,353 801,882 559,287 $ 30,335,588 $ 23,480,554 $ 22,768,874

Financial instruments (Tables)

Financial instruments (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about financial instruments [abstract]
Schedule of comparison by class of the carrying amounts and fair value of the company's financial instruments	As at December 31 2018 2017 Carrying Fair Carrying Fair Financial assets Financial assets measured at amortized cost Cash and cash equivalents $ 24,139,281 $ 24,139,281 $ 5,260,480 $ 5,260,480 Short-term investments 47,747,000 47,747,000 - - Accounts receivable 10,764,579 10,764,579 8,588,255 8,588,255 Consideration receivable - - 82,678,366 82,678,366 Holdback receivable 11,909,368 11,909,368 12,068,773 12,068,773 Financial liabilities Financial liabilities measured at amortized cost: Accounts payable and accrued liabilities $ 14,378,215 $ 14,378,215 $ 10,371,103 $ 10,371,103 Accrued transaction costs - - 22,360,730 22,360,730 Current portion of royalty obligation 1,495,548 1,495,548 1,537,202 1,537,202 Royalty obligation 2,035,010 2,035,010 2,911,810 2,911,810 License fee payable - - 501,800 501,800 Other long-term liability 1,200,608 1,200,608 1,135,007 1,135,007
Schedule of fair value of financial assets and liabilities	The fair value hierarchy of the following financial assets and liabilities on the consolidated statements of financial position as at December 31, 2018 is as follows: Level 1 Level 2 Level 3 Financial assets Holdback receivable $ - $ - $ 11,909,368 Financial liabilities Accounts payable and accrued liabilities $ - $ - $ 545,680 Current portion of royalty obligation - - 1,495,548 Royalty obligation - - 2,035,010 Other long-term liabilities - - 1,200,608 The fair value hierarchy of the following financial assets and liabilities on the consolidated statements of financial position as at December 31, 2017 is as follows: Level 1 Level 2 Level 3 Financial assets Assets held for sale $ - $ 14,052,861 $ - Holdback receivable - - 12,068,773 Financial liabilities Accounts payable and accrued liabilities $ - $ - $ 877,150 Current portion of royalty obligation - - 1,537,202 Liabilities held for sale - 6,976,313 - Royalty obligation - - 2,911,810 License fee payable - - 501,800 Other long-term liability - - 1,135,007
Schedule for exposure to U.S. dollar currency risk through financial assets and liabilities	As at December 31 (Expressed in U.S. Dollars) 2018 2017 Cash $ 17,427,653 $ 4,086,080 Short-term investments 35,000,000 - Accounts receivable 7,725,228 6,792,664 Consideration receivable - 65,905,433 Holdback receivable 8,729,928 9,620,385 Accounts payable and accrued liabilities (9,902,571 ) (7,174,456 ) Accrued transaction costs - (17,824,416 ) Income taxes payable (775,903 ) (1,935,879 ) Current portion of royalty obligation (1,096,282 ) (1,225,350 ) Royalty obligation (1,491,724 ) (2,321,092 ) License fee payable - (400,000 ) Other long-term liability (880,082 ) (904,749 ) $ 54,736,247 $ 54,618,620

Segmented information (Tables)

Segmented information (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of operating segments [abstract]
Schedule of geographical areas of property, plant and equipment and intangible assets	As at December 31 2018 2017 Canada $ 316,013 $ 218,488 Barbados 1,705,250 1,756,300 United States - 3,134 $ 2,021,263 $ 1,977,922

Significant accounting polici_4

Significant accounting policies (Details)	12 Months Ended
	Dec. 31, 2018
Computers, office equipment, furniture and fixtures
Disclosure of detailed information about property, plant and equipment [line items]
Method of depreciation	Straight-line/Diminishing balance
Depreciation rates	20% to 25
Leasehold improvements
Disclosure of detailed information about property, plant and equipment [line items]
Method of depreciation	Straight-line
Depreciation rates	Term of lease

Discontinued operations (Detail

Discontinued operations (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Detailed Information Discontinued Operations [Line Items]
Revaluation of long-term derivative			$ (20,560,440)
Gain on step acquisition			(4,895,573)
Gain on disposition of the Apicore business		$ 55,254,236
Income from discontinued operations	$ 0	31,924,191	23,358,318
Apicore
Disclosure Of Detailed Information Discontinued Operations [Line Items]
Revenue	0	22,759,385	7,798,838
Expenses	0	(47,936,485)	(9,263,926)
Revaluation of long-term derivative	0	0	20,560,440
Gain on step acquisition	0	0	4,895,573
(Loss) income from discontinued operations		(25,177,100)	23,990,925
Income tax recovery (expense)	0	1,847,055	(632,607)
Loss (income) after income tax recovery (expense)	0	23,330,045	(23,358,318)
Gain on disposition of the Apicore business		55,254,236
Income from discontinued operations	$ 0	$ 31,924,191	$ 23,358,318

Discontinued operations (Deta_2

Discontinued operations (Details 1) - Apicore - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Detailed Information Discontinued Operations [Line Items]
Net cash flows used in operating activities	$ 0	$ 5,210,341	$ (1,295,487)
Net cash flows from (used in) investing activities	0	54,326,360	(421,077)
Net cash flows from (used in) financing activities	0	(80,944,373)	44,294,204
Net cash flows used in discontinued operations	$ 0	$ (21,407,672)	$ 42,577,640

Discontinued operations (Deta_3

Discontinued operations (Detail Textuals)	Oct. 02, 2017CAD ($)	Oct. 02, 2017USD ($)	Dec. 31, 2018CAD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017CAD ($)	Dec. 31, 2016CAD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2017USD ($)
Disclosure Of Detailed Information Discontinued Operations [Line Items]
Initial value of holdback receivable			$ 11,909,368		$ 12,068,773
Revaluation of holdback receivable			1,472,999		(82,489)
Foreign exchange gain (loss)			$ 6,460,805		175,459	$ (262,469)
Apicore
Disclosure Of Detailed Information Discontinued Operations [Line Items]
Closing payment received upon closing of sale transaction	$ 72,057,718	$ 57,623,125
Consideration receivable, net of transaction costs					65,234,555			$ 52,886,588
Write-down recognized to reduce carrying amount of assets					1,791,484
Carrying amount of the assets in the disposal group to their fair value less costs to sell				$ 0	$ 7,076,548		$ 0

Accounts receivable (Details)

Accounts receivable (Details) - CAD ($)	Dec. 31, 2018	Dec. 31, 2017
Trade and other receivables [abstract]
Trade accounts receivable	$ 9,677,847	$ 8,496,281
Other accounts receivable	1,086,732	91,974
Accounts receivable	$ 10,764,579	$ 8,588,255

Accounts receivable (Detail Tex

Accounts receivable (Detail Textuals) - Customer	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of major customers [line items]
Number of customers owing greater than 10% of accounts receivable	3	3
Concentration Risk, Percentage Of Accounts Receivable	91.00%	96.00%
Customer A
Disclosure of major customers [line items]
Concentration Risk, Percentage Of Accounts Receivable	47.00%	41.00%
Customer B
Disclosure of major customers [line items]
Concentration Risk, Percentage Of Accounts Receivable	22.00%	32.00%
Customer C
Disclosure of major customers [line items]
Concentration Risk, Percentage Of Accounts Receivable	22.00%	23.00%

Inventories (Details)

Inventories (Details) - CAD ($)	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Inventories [Abstract]
Finished product available-for-sale	$ 2,936,883	$ 2,058,776
Unfinished product and packaging materials	1,302,384	1,016,230
Current inventories	$ 4,239,267	$ 3,075,006

Inventories (Detail Textuals)

Inventories (Detail Textuals) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Inventories [Abstract]
Cost of goods sold, inventory	$ 3,861,745	$ 3,079,397	$ 2,482,986
Wrote-off (reversal) of inventory	$ 94,517	$ 385,289	$ (108,817)

Property, plant and equipment_2

Property, plant and equipment (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about property, plant and equipment [line items]
Balance	$ 221,622
Amortization	103,207	$ 1,173,019	$ 189,008
Acquisitions under business combinations	(197,494)	(1,194,703)	(464,208)
Balance	316,013	221,622
Cost
Disclosure of detailed information about property, plant and equipment [line items]
Balance	584,508	10,680,709
Additions	197,494	1,056,705
Transfers to assets held for resale		(13,899,734)
Effect of movements in exchange rates	12,078	2,746,828
Dispositions	(156,280)
Balance	637,800	584,508	10,680,709
Accumulated amortization and impairment losses
Disclosure of detailed information about property, plant and equipment [line items]
Balance	362,886	380,070
Amortization	103,207	1,173,019
Transfers to assets held for resale		(1,149,352)
Effect of movements in exchange rates	11,974	(40,851)
Dispositions	(156,280)
Balance	321,787	362,886	380,070
Land
Disclosure of detailed information about property, plant and equipment [line items]
Balance	0
Balance	0	0
Land | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Balance	0	2,316,979
Additions	0	0
Transfers to assets held for resale		(2,317,273)
Effect of movements in exchange rates	0	294
Dispositions	0
Balance	0	0	2,316,979
Land | Accumulated amortization and impairment losses
Disclosure of detailed information about property, plant and equipment [line items]
Balance	0	0
Amortization	0	0
Transfers to assets held for resale		0
Effect of movements in exchange rates	0	0
Dispositions	0
Balance	0	0	0
Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Balance	0
Balance	0	0
Buildings | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Balance	0	2,122,687
Additions	0	82,163
Transfers to assets held for resale		(2,900,284)
Effect of movements in exchange rates	0	695,434
Dispositions	0
Balance	0	0	2,122,687
Buildings | Accumulated amortization and impairment losses
Disclosure of detailed information about property, plant and equipment [line items]
Balance	0	21,408
Amortization	0	291,638
Transfers to assets held for resale		(306,761)
Effect of movements in exchange rates	0	(6,285)
Dispositions	0
Balance	0	0	21,408
Computer And Office Equipment
Disclosure of detailed information about property, plant and equipment [line items]
Balance	146,898
Balance	257,213	146,898
Computer And Office Equipment | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Balance	428,165	2,439,071
Additions	185,682	675,788
Transfers to assets held for resale		(3,319,298)
Effect of movements in exchange rates	12,078	632,604
Dispositions	(156,280)
Balance	469,645	428,165	2,439,071
Computer And Office Equipment | Accumulated amortization and impairment losses
Disclosure of detailed information about property, plant and equipment [line items]
Balance	281,267	250,261
Amortization	75,471	339,358
Transfers to assets held for resale		(286,632)
Effect of movements in exchange rates	11,974	(21,720)
Dispositions	(156,280)
Balance	212,432	281,267	250,261
Machinery and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Balance	0
Balance	0	0
Machinery and equipment | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Balance	0	2,798,482
Additions	0	298,754
Transfers to assets held for resale		(4,572,065)
Effect of movements in exchange rates	0	1,474,829
Dispositions	0
Balance	0	0	2,798,482
Machinery and equipment | Accumulated amortization and impairment losses
Disclosure of detailed information about property, plant and equipment [line items]
Balance	0	67,541
Amortization	0	384,486
Transfers to assets held for resale		(443,746)
Effect of movements in exchange rates	0	(8,281)
Dispositions	0
Balance	0	0	67,541
Leasehold improvements
Disclosure of detailed information about property, plant and equipment [line items]
Balance	74,724
Balance	58,800	74,724
Leasehold improvements | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Balance	156,343	1,003,490
Additions	11,812	0
Transfers to assets held for resale		(790,814)
Effect of movements in exchange rates	0	(56,333)
Dispositions	0
Balance	168,155	156,343	1,003,490
Leasehold improvements | Accumulated amortization and impairment losses
Disclosure of detailed information about property, plant and equipment [line items]
Balance	81,619	40,860
Amortization	27,736	157,537
Transfers to assets held for resale		(112,213)
Effect of movements in exchange rates	0	(4,565)
Dispositions	0
Balance	$ 109,355	$ 81,619	$ 40,860

Property, plant and equipment_3

Property, plant and equipment (Detail Textuals) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about property, plant and equipment [line items]
Amortization of property, plant and equipment	$ 103,207	$ 1,173,019	$ 189,008
Discontinued Operations
Disclosure of detailed information about property, plant and equipment [line items]
Amortization of property, plant and equipment		1,075,225	105,724
Discontinued Operations | Selling, general and administrative expense
Disclosure of detailed information about property, plant and equipment [line items]
Amortization of property, plant and equipment	$ 103,207	$ 97,794	$ 83,284

Intangible assets (Details)

Intangible assets (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about intangible assets [line items]
Beginning balance	$ 1,756,300
Amortization	195,977	$ 6,633,957	$ 2,192,024
Ending balance	1,705,250	1,756,300
Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	20,717,342	122,006,554
Additions		2,383,550
Impairment		(635,721)
Transfers to assets held for resale		(94,948,759)
Effect of movements in exchange rates	1,811,632	(8,088,282)
Ending balance	22,528,974	20,717,342	122,006,554
Accumulated amortization and impairment losses
Disclosure of detailed information about intangible assets [line items]
Beginning balance	18,961,042	21,141,737
Amortization	195,977	6,633,957
Transfers to assets held for resale		(7,121,157)
Effect of movements in exchange rates	1,666,705	(1,693,495)
Ending balance	20,823,724	18,961,042	21,141,737
Licences
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,756,300
Ending balance	1,705,250	1,756,300
Licences | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,756,300	0
Additions		2,383,550
Impairment		(635,721)
Transfers to assets held for resale		0
Effect of movements in exchange rates	153,580	8,471
Ending balance	1,909,880	1,756,300	0
Licences | Accumulated amortization and impairment losses
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	0
Amortization	195,977	0
Transfers to assets held for resale		0
Effect of movements in exchange rates	8,653	0
Ending balance	204,630	0	0
Patents
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0
Ending balance	0	0
Patents | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	14,238,712	25,012,530
Additions		0
Impairment		0
Transfers to assets held for resale		(9,122,874)
Effect of movements in exchange rates	1,245,105	(1,650,944)
Ending balance	15,483,817	14,238,712	25,012,530
Patents | Accumulated amortization and impairment losses
Disclosure of detailed information about intangible assets [line items]
Beginning balance	14,238,712	15,321,230
Amortization	0	637,406
Transfers to assets held for resale		(684,216)
Effect of movements in exchange rates	1,245,105	(1,035,708)
Ending balance	15,483,817	14,238,712	15,321,230
Trademarks
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0
Ending balance	0	0
Trademarks | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	4,013,981	4,296,192
Additions		0
Impairment		0
Transfers to assets held for resale		0
Effect of movements in exchange rates	351,004	(282,211)
Ending balance	4,364,985	4,013,981	4,296,192
Trademarks | Accumulated amortization and impairment losses
Disclosure of detailed information about intangible assets [line items]
Beginning balance	4,013,981	4,296,192
Amortization	0	0
Transfers to assets held for resale		0
Effect of movements in exchange rates	351,004	(282,211)
Ending balance	4,364,985	4,013,981	4,296,192
Customer list
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0
Ending balance	0	0
Customer list | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	708,349	7,472,143
Additions		0
Impairment		0
Transfers to assets held for resale		(6,267,525)
Effect of movements in exchange rates	61,943	(496,269)
Ending balance	770,292	708,349	7,472,143
Customer list | Accumulated amortization and impairment losses
Disclosure of detailed information about intangible assets [line items]
Beginning balance	708,349	814,101
Amortization	0	437,904
Transfers to assets held for resale		(470,064)
Effect of movements in exchange rates	61,943	(73,592)
Ending balance	770,292	708,349	814,101
Approved ANDAs
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0
Ending balance	0	0
Approved ANDAs | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	1,505,664
Additions		0
Impairment		0
Transfers to assets held for resale		(1,405,541)
Effect of movements in exchange rates	0	(100,123)
Ending balance	0	0	1,505,664
Approved ANDAs | Accumulated amortization and impairment losses
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	12,548
Amortization	0	98,203
Transfers to assets held for resale		(105,416)
Effect of movements in exchange rates	0	(5,335)
Ending balance	0	0	12,548
Acquired in process research and development
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0
Ending balance	0	0
Acquired in process research and development | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	83,720,025
Additions		0
Impairment		0
Transfers to assets held for resale		(78,152,819)
Effect of movements in exchange rates	0	(5,567,206)
Ending balance	0	0	83,720,025
Acquired in process research and development | Accumulated amortization and impairment losses
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	697,666
Amortization	0	5,460,444
Transfers to assets held for resale		(5,861,461)
Effect of movements in exchange rates	0	(296,649)
Ending balance	$ 0	$ 0	$ 697,666

Intangible assets (Detail Textu

Intangible assets (Detail Textuals) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about intangible assets [line items]
Amortization of the acquired intangible assets	$ 195,977	$ 6,633,957	$ 2,192,024
Intangible assets other than goodwill	1,705,250	1,756,300
License fee payable		501,800
License fee payable
Disclosure of detailed information about intangible assets [line items]
Amount payable for services provided recorded within accounts payable and accrued liabilities	545,680	501,800
Cost
Disclosure of detailed information about intangible assets [line items]
Write-down of intangible assets		(635,721)
Intangible assets other than goodwill	22,528,974	20,717,342	122,006,554
Additions		2,383,550
Accumulated amortization and impairment losses
Disclosure of detailed information about intangible assets [line items]
Amortization of the acquired intangible assets	195,977	6,633,957
Intangible assets other than goodwill	20,823,724	18,961,042	21,141,737
Acquired intangible assets
Disclosure of detailed information about intangible assets [line items]
Amortization of the acquired intangible assets		6,633,957	841,754
Trademarks
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill	0	0
Trademarks | Cost
Disclosure of detailed information about intangible assets [line items]
Write-down of intangible assets		0
Intangible assets other than goodwill	4,364,985	4,013,981	4,296,192
Additions		0
Trademarks | Accumulated amortization and impairment losses
Disclosure of detailed information about intangible assets [line items]
Amortization of the acquired intangible assets	0	0
Intangible assets other than goodwill	4,364,985	4,013,981	4,296,192
Trademarks | AGGRASTAT
Disclosure of detailed information about intangible assets [line items]
Amortization of intangible assets recognized in cost of goods sold			1,347,022
Amortization of intangible assets recognized in research and development expenses			3,268
Licences
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill	1,705,250	1,756,300
Licences | Cost
Disclosure of detailed information about intangible assets [line items]
Write-down of intangible assets		(635,721)
Intangible assets other than goodwill	1,909,880	1,756,300	0
Additions		2,383,550
Licences | Accumulated amortization and impairment losses
Disclosure of detailed information about intangible assets [line items]
Amortization of the acquired intangible assets	195,977	0
Intangible assets other than goodwill	$ 204,630	$ 0	$ 0

Holdback receivable (Detail Tex

Holdback receivable (Detail Textuals) $ in Millions	12 Months Ended
	Dec. 31, 2018CAD ($)	Dec. 31, 2017CAD ($)	Oct. 02, 2017CAD ($)	Oct. 02, 2017USD ($)
Disclosure Of Holdback Receivable [Line Items]
Holdback receivable (Note 5&10)	$ 11,909,368	$ 12,068,773
Amount of allowance against the holdback receivable	1,472,999	(82,489)
Other liabilities	1,200,608	1,135,007
Apicore
Disclosure Of Holdback Receivable [Line Items]
Holdback receivable (Note 5&10)			$ 11,940,736	$ 10
Other liabilities	$ 1,200,608	$ 1,135,007

Royalty obligation (Detail Text

Royalty obligation (Detail Textuals) - CAD ($)	1 Months Ended	12 Months Ended
	Jul. 18, 2011	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Royalty Obligation [Line Items]
Fair value of the royalty obligation		$ 901,915
Carrying value of the royalty obligation		3,530,558	$ 4,449,012
Current portion of the royalty obligation		1,495,548	1,537,202
Change in royalty obligation		355,287	747,540	$ 2,271,436
Royalties received		1,654,380	1,242,587	1,795,089
Royalties paid		$ (1,538,766)	$ (1,829,295)	$ (1,712,390)
Birmingham Associates Ltd | AGGRASTAT
Royalty Obligation [Line Items]
Value of shares issued on debt conversion	$ 4,750,000
Number of shares issued on debt conversion	2,176,003
Percentage of first $2,000,000 of quarterly sales	4.00%
Percentage of quarterly sales between $2,000,000 and $4,000,000	6.00%
Percentage of portion of quarterly sales exceeding $4,000,000 payable within 60 days	8.00%
Amount of quarterly product revenue	$ 2,000,000
Amount of quarterly product revenue	2,000,000
Amount of quarterly product revenue	4,000,000
Amount of quarterly product revenue	$ 4,000,000

Capital Stock (Details)

Capital Stock (Details) - CAD ($)		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Amount of common shares
Balance		$ 80,709,160	$ 38,283,904	$ 4,461,551
Shares issued upon exercise of stock options		363,458	519,999	1,844,130
Shares issued upon exercise of warrants			92,332	39,172
Balance		$ 83,593,545	$ 80,709,160	$ 38,283,904
Share Capital
Number of common shares
Balance		15,782,327	15,532,408
Shares issued upon exercise of stock options		206,885	207,950
Shares issued upon exercise of warrants			41,969
Shares repurchased and cancelled under a normal course issuer bid	[1]	(441,400)
Balance		15,547,812	15,782,327	15,532,408
Amount of common shares
Balance		$ 125,733,727	$ 124,700,345	$ 121,413,777
Shares issued upon exercise of stock options		654,711	869,703	3,217,125
Shares issued upon exercise of warrants			163,679	69,443
Shares repurchased and cancelled under a normal course issuer bid	[1]	(3,501,333)
Balance		$ 122,887,105	$ 125,733,727	$ 124,700,345
[1]	On May 16, 2018, the Company announced that the TSX-V accepted the Company's notice of intention to make a normal course issuer bid ("NCIB"). Under the terms of the NCIB, the Company may acquire up to an aggregate of 794,088 common shares representing five percent of the common shares outstanding, over the twelve-month period that the NCIB is in place. The NCIB commenced on May 28, 2018 and will end on May 27, 2019, or on such earlier date as the Company may complete its maximum purchases under the NCIB. The prices that the Company will pay for common shares purchased will be the market price of the shares at the time of purchase.

Capital Stock (Details 1)

Capital Stock (Details 1)	12 Months Ended
	Dec. 31, 2018CAD ($)Share	Dec. 31, 2017CAD ($)Share	Dec. 31, 2016CAD ($)Share
Options
Balance | Share	1,602,127	1,387,000	2,277,126
Granted | Share	200,000	476,000	265,025
Exercised | Share	(206,885)	(207,950)	(1,069,434)
Forfeited, cancelled or expired | Share	(200,600)	(52,923)	(85,717)
Balance | Share	1,394,642	1,602,127	1,387,000
Options exercisable, end of period | Share	1,044,892	1,231,127	1,387,000
Weighted average exercise price
Balance | $	$ 3.58	$ 2.37	$ 1.90
Granted | $	7.25	7.20	6.16
Exercised | $	(1.76)	(2.50)	(1.72)
Forfeited, cancelled or expired | $	(6.85)	(8.58)	(9.59)
Balance | $	3.91	3.58	2.37
Options exercisable, end of period | $	$ 2.80	$ 2.50	$ 2.37

Capital Stock (Details 2)

Capital Stock (Details 2)	Dec. 31, 2018CAD ($)ShareYears	Dec. 31, 2017CAD ($)Share	Dec. 31, 2016CAD ($)Share	Dec. 31, 2015CAD ($)Share
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	1,394,642	1,602,127	1,387,000	2,277,126
Options outstanding weighted average exercise price	$ 3.91	$ 3.58	$ 2.37	$ 1.90
Options exercisable, end of period | Share	1,044,892	1,231,127	1,387,000
$0.30
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Range of exercise prices	$ 0.30
Number outstanding | Share	185,000
Weighted average remaining contractual life (in years) | Years	4.35
Options outstanding weighted average exercise price	$ 0.30
Options exercisable, end of period | Share	185,000
$0.31 - $1.00
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	5,334
Weighted average remaining contractual life (in years) | Years	0.29
Options outstanding weighted average exercise price	$ 0.60
Options exercisable, end of period | Share	5,334
$0.31 - $1.00 | Bottom of range
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Range of exercise prices	$ 0.31
$0.31 - $1.00 | Top of range
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Range of exercise prices	$ 1
$1.01 - $3.00
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	549,433
Weighted average remaining contractual life (in years) | Years	3.35
Options outstanding weighted average exercise price	$ 1.59
Options exercisable, end of period | Share	549,433
$1.01 - $3.00 | Bottom of range
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Range of exercise prices	$ 1.01
$1.01 - $3.00 | Top of range
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Range of exercise prices	$ 3
$3.01 - $5.00
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	32,500
Weighted average remaining contractual life (in years) | Years	1.90
Options outstanding weighted average exercise price	$ 3.90
Options exercisable, end of period | Share	32,500
$3.01 - $5.00 | Bottom of range
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Range of exercise prices	$ 3.01
$3.01 - $5.00 | Top of range
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Range of exercise prices	$ 5
$5.01 - $7.30
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	622,375
Weighted average remaining contractual life (in years) | Years	3.89
Options outstanding weighted average exercise price	$ 7.06
Options exercisable, end of period | Share	272,625
$5.01 - $7.30 | Bottom of range
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Range of exercise prices	$ 5.01
$5.01 - $7.30 | Top of range
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Range of exercise prices	$ 7.30
$0.30 - $7.30
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	1,394,642
Weighted average remaining contractual life (in years) | Years	3.68
Options outstanding weighted average exercise price	$ 3.91
Options exercisable, end of period | Share	1,044,892
$0.30 - $7.30 | Bottom of range
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Range of exercise prices	$ 0.30
$0.30 - $7.30 | Top of range
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Range of exercise prices	$ 7.30

Capital Stock (Details 3)

Capital Stock (Details 3) - Years	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of range of exercise prices of outstanding share options [line items]
Expected option life (in years)	4.4	4.5
Risk free interest rate		1.71%
Dividend yield	0.00%	0.00%
Expected volatility		80.44%
Bottom of range
Disclosure of range of exercise prices of outstanding share options [line items]
Expected option life (in years)			4.8
Risk free interest rate	1.92%		0.52%
Expected volatility	85.14%		115.59%
Top of range
Disclosure of range of exercise prices of outstanding share options [line items]
Expected option life (in years)			5
Risk free interest rate	2.04%		0.67%
Expected volatility	93.72%		117.56%

Capital Stock (Details 4)

Capital Stock (Details 4)	12 Months Ended
	Dec. 31, 2018CAD ($)Share	Dec. 31, 2017CAD ($)Share	Dec. 31, 2016CAD ($)Share
Warrants
Balance, beginning of period | Share	900,000	941,969	59,775
Granted | Share	0	0	900,000
Exercised | Share	0	(41,969)	(17,806)
Balance, end of period | Share	900,000	900,000	941,969
Warrants exercisable, end of period | Share	900,000	900,000	941,969
Weighted average exercise price
Balance, beginning of period | $	$ 6.50	$ 6.31	$ 2.20
Granted | $	0	0	6.50
Exercised | $	0	(2.20)	(2.20)
Balance, end of period | $	6.50	6.50	6.31
Warrants exercisable, end of period | $	$ 6.50	$ 6.50	$ 6.31

Capital Stock (Details 5)

Capital Stock (Details 5) - Years	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected option life (in years)	4.4	4.5
Risk free interest rate		1.71%
Dividend yield	0.00%	0.00%
Expected volatility		80.44%
Class D warrants
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected option life (in years)			4
Risk free interest rate			0.85%
Dividend yield			0.00%
Expected volatility			120.40%

Capital Stock (Details 6)

Capital Stock (Details 6) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Basic earnings per share
Net earnings before discontinued operations	$ 0.25	$ 0.74	$ 0.24
Income from discontinued operations, net of tax	0	2.04	1.56
Total	0.25	2.78	1.80
Diluted earnings per share
Net earnings before discontinued operations	0.24	0.63	0.21
Earnings from discontinued operations, net of tax	0	1.76	1.35
Total	$ 0.24	$ 2.39	$ 1.56

Capital Stock (Details 7)

Capital Stock (Details 7) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Capital Stock [Abstract]
Net earnings before discontinued operations	$ 3,925,639	$ 11,496,693	$ 3,624,323
Net income from discontinued operations, net of tax	0	31,924,191	23,358,318
Net income	$ 3,925,639	$ 43,420,884	$ 26,982,641
Weighted average ordinary shares and adjusted weighted average ordinary shares [abstract]
Weighted average shares outstanding for basic earnings per share	15,791,396	15,636,853	15,002,005
Effects of dilution from:
Stock options	772,267	1,601,227	1,372,427
Warrants	0	900,000	941,969
Weighted average shares outstanding for diluted earnings per share	16,563,663	18,138,080	17,316,401

Capital Stock (Detail Textuals)

Capital Stock (Detail Textuals)	12 Months Ended
	Dec. 31, 2018CAD ($)shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock options vesting term	five-year
Aggregate percentage of common stock share outstanding	5.00%
Aggregate common stock share outstanding normal course issuer Bid | shares	794,088
Repurchase of common shares under normal course issuer Bid | $	$ 3,021,340
Repurchase additional common stock share | shares	159,900
Cancellation of additional common shares | $	$ 999,826
Deficit
Disclosure of terms and conditions of share-based payment arrangement [line items]
Buy-back of common shares | $	479,993
Share Capital
Disclosure of terms and conditions of share-based payment arrangement [line items]
Shares repurchased and cancelled under a normal course issuer bid | $	$ 3,501,333	[1]
Shares repurchased and cancelled under a normal course issuer bid | shares	441,400	[1]
Top of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of common shares reserved for issuance of stock options | shares	2,934,403
Stock options term	10 years
Bottom of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock options term	5 years
[1]	On May 16, 2018, the Company announced that the TSX-V accepted the Company's notice of intention to make a normal course issuer bid ("NCIB"). Under the terms of the NCIB, the Company may acquire up to an aggregate of 794,088 common shares representing five percent of the common shares outstanding, over the twelve-month period that the NCIB is in place. The NCIB commenced on May 28, 2018 and will end on May 27, 2019, or on such earlier date as the Company may complete its maximum purchases under the NCIB. The prices that the Company will pay for common shares purchased will be the market price of the shares at the time of purchase.

Capital Stock (Detail Textuals

Capital Stock (Detail Textuals 1)	Jul. 03, 2017CAD ($)Shareshares	Dec. 31, 2018CAD ($)Share	Dec. 31, 2017CAD ($)Shareshares	Dec. 31, 2017USD ($)Shareshares	Dec. 31, 2016CAD ($)Share	Dec. 31, 2015CAD ($)Share	Dec. 31, 2017USD ($)Shareshares	Dec. 01, 2016Share
Disclosure of detailed information about business combination [line items]
Compensation expense related to stock options granted | $		$ 1,022,176	$ 490,769		$ 1,340,001
Gross proceeds from sale of options | $		$ 363,458	$ 519,999		$ 1,844,130
Number of share options expired without being exercised | Share		200,600	52,923	52,923	85,717
Number of stock options outstanding | Share		1,394,642	1,602,127		1,387,000	2,277,126	1,602,127
Apicore entity | Discontinued Operations
Disclosure of detailed information about business combination [line items]
Compensation expense related to stock options granted | $			$ 132,346			$ 60,240
Apicore
Disclosure of detailed information about business combination [line items]
Number of shares and options authorized | Share								497,500
Number of shares outstanding | shares	117,500
Non-controlling interests | $	$ 615,381
Apicore | Class E common shares
Disclosure of detailed information about business combination [line items]
Number of shares and options authorized | Share								400,000
Number of share options expired without being exercised | Share	117,500
Apicore | Apicore entity | Class E common shares
Disclosure of detailed information about business combination [line items]
Number of shares and options authorized | Share								897,500
Employees and former directors | Class E common shares
Disclosure of detailed information about business combination [line items]
Gross proceeds from sale of options | $				$ 48,375
Number of share acquired due to options exercised | shares			405,000	405,000
Total cost			$ 2,690,383				$ 1,974,772
Number of shares outstanding | shares			112,500				112,500
Employees and former directors | Apicore entity
Disclosure of detailed information about business combination [line items]
Gross proceeds from sale of options | $				$ 280,125
Employees and former directors | Apicore entity | Class E common shares
Disclosure of detailed information about business combination [line items]
Number of shares issued under the plan | shares			292,500	292,500

Capital Stock (Detail Textual_2

Capital Stock (Detail Textuals 2) - Apicore - Crown Capital Fund IV LP term loan	1 Months Ended
	Nov. 17, 2016CAD ($)Share$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of warrants issued to lenders | Share	900,000
Maturity period of term loans	48 months
Warrant exercise price issued to lenders | $ / shares	$ 6.50
Fair value assigned to warrants issued	$ 2,065,500
Pro rata share of financing costs	$ 116,695

Capital Stock (Detail Textual_3

Capital Stock (Detail Textuals 3) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Capital Stock [Abstract]
Anti-dilutive stock option excluded from calculation of diluted earnings per share before discontinued operations as exercise price exceeded the share price on TSX Venture Exchange	622,375	900	14,573
Anti-dilutive warrants excluded from calculation of diluted earnings per share before discontinued operations as exercise price exceeded the share price on TSX Venture Exchange	900,000

Income taxes (Details)

Income taxes (Details) - CAD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets
Non-capital loss carryforwards	$ 127,176	$ 326,108
Total deferred tax assets	$ 127,176	$ 326,108

Income taxes (Details 1)

Income taxes (Details 1) - CAD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets
Scientific research and experimental development	$ 3,237,000	$ 3,574,000
Holdback receivable	199,000
Other	159,000	315,000
Total deferred tax assets	$ 3,595,000	$ 3,889,000

Income taxes (Details 2)

Income taxes (Details 2) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income (loss) for the year
Canadian	$ 3,439,883	$ (2,178,334)	$ (4,012,706)
Foreign	1,382,632	4,615,378	7,807,249
Income (loss) for the year	4,822,515	2,437,044	3,794,543
Canadian federal and provincial income taxes at 27% (2017 - 27%; 2016 - 27%)	(1,302,000)	(658,000)	(1,025,000)
Permanent differences and other items	26,000	(335,000)	(758,000)
Foreign tax rate in foreign jurisdictions	85,000	656,000	2,159,000
Change in unrecognized deferred tax assets	294,000	9,397,000	(546,000)
Income tax expense	$ (896,876)	$ 9,059,649	$ (170,220)

Income taxes (Details 3)

Income taxes (Details 3) - Barbados	Dec. 31, 2018CAD ($)
Income Tax [Line Items]
Losses available for application in future years	$ 5,088,000
2019
Income Tax [Line Items]
Losses available for application in future years	2,478,000
2020
Income Tax [Line Items]
Losses available for application in future years	1,271,000
2022
Income Tax [Line Items]
Losses available for application in future years	$ 1,339,000

Income taxes (Detail Textuals)

Income taxes (Detail Textuals) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Abstract]
Current income tax expense	$ 677,900	$ (9,392,836)	$ 501,315
Deferred income tax expense (recovery)	$ 218,976	$ 333,187	$ (331,095)

Income taxes (Detail Textuals 1

Income taxes (Detail Textuals 1)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax [Line Items]
Statutory income tax rate	27.00%	27.00%	27.00%
Barbados
Income Tax [Line Items]
Statutory income tax rate	2.50%
MAURITIUS
Income Tax [Line Items]
Statutory income tax rate	15.00%
IRELAND
Income Tax [Line Items]
Statutory income tax rate	12.50%
United States
Income Tax [Line Items]
Statutory income tax rate	21.00%

Finance income (expense) (Detai

Finance income (expense) (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule For Finance Income And Expense [Line Items]
Interest income	$ 1,114,676	$ 47,447	$ 30,452
Accretion of royalty obligation	(355,287)	(747,540)	(2,271,436)
Accretion on holdback receivable	325,522	0	0
Bank charges and other interest	(23,979)	(31,698)	(20,224)
Change in fair value of warrant liability	0	0	1,161
Total Finance costs (income)	1,060,932	(837,461)	(2,478,914)
MIOP loan
Schedule For Finance Income And Expense [Line Items]
Interest on MIOP loan	$ 0	$ (105,670)	$ (218,867)

Finance income (expense) (Det_2

Finance income (expense) (Details 1) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule For Finance Income And Expense [Line Items]
Interest received	$ 279,098	$ 47,447	$ 30,452
Other interest, net and banking fees	(23,979)	(31,698)	(20,224)
Finance income (expense) (paid) received	255,119	73,079	176,239
MIOP loan
Schedule For Finance Income And Expense [Line Items]
Interest paid	$ 0	$ (88,828)	$ (186,467)

Commitments and contingencies_2

Commitments and contingencies (Details)	Dec. 31, 2018CAD ($)
Commitments And Contingencies [Line Items]
Future payable representing contracts and other commitments	$ 9,224,420
2019
Commitments And Contingencies [Line Items]
Future payable representing contracts and other commitments	4,005,841
2020
Commitments And Contingencies [Line Items]
Future payable representing contracts and other commitments	2,240,096
2021
Commitments And Contingencies [Line Items]
Future payable representing contracts and other commitments	1,274,935
2022
Commitments And Contingencies [Line Items]
Future payable representing contracts and other commitments	1,294,288
2023
Commitments And Contingencies [Line Items]
Future payable representing contracts and other commitments	204,630
Thereafter
Commitments And Contingencies [Line Items]
Future payable representing contracts and other commitments	$ 204,630

Commitments and contingencies_3

Commitments and contingencies (Detail Textuals)	Jan. 01, 2019CAD ($)	Nov. 01, 2014	Oct. 31, 2017USD ($)	Dec. 31, 2018CAD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2018EUR (€)	Nov. 01, 2018CAD ($)
Commitments And Contingencies [Line Items]
Unfinished product inventory					$ 197,900
Business and administration agreement with GVI
Commitments And Contingencies [Line Items]
Term of agreement	1 year
Amount committed to pay under the agreement, per month	$ 7,083
Amount committed to pay under the agreement, per year	$ 85,000
Bottom of range
Commitments And Contingencies [Line Items]
Unfinished product inventory | €						€ 400,000
Top of range
Commitments And Contingencies [Line Items]
Unfinished product inventory | €						€ 525,000
Sublease agreement with GVI
Commitments And Contingencies [Line Items]
Term of agreement		3 years
Sublease rent upto 30th April, 2016				$ 170,000
Sublease rent from 1st May, 2016				$ 212,000			$ 306,400
Additional period for renewal of lease term				5 years
AGGRASTAT
Commitments And Contingencies [Line Items]
Unfinished product inventory					$ 150,000
Prexxartan | Exclusive License Agreement
Commitments And Contingencies [Line Items]
Term of agreement			7 years
Upfront payment			$ 100,000
Additional amount payable			$ 400,000

Commitments and contingencies_4

Commitments and contingencies (Detail Textuals 1)	12 Months Ended
	Dec. 31, 2018CAD ($)	Dec. 31, 2018EUR (€)	Dec. 31, 2017CAD ($)	Dec. 31, 2016CAD ($)
Commitments And Contingencies [Line Items]
Royalty expense	$ 1,654,380		$ 1,242,587	$ 1,795,089
Royalty payment	$ (1,538,766)		$ (1,829,295)	$ (1,712,390)
Payment for expansion of label | €		€ 300,000
Period over which contingent liability is payable	3 years	3 years
Birmingham Associates Ltd | AGGRASTAT
Commitments And Contingencies [Line Items]
Terms of quarterly sales	60 days	60 days
Birmingham Associates Ltd | AGGRASTAT | Upto 200000
Commitments And Contingencies [Line Items]
Percentage of royalty	4.00%	4.00%
Birmingham Associates Ltd | AGGRASTAT | Between 200000 and 400000
Commitments And Contingencies [Line Items]
Percentage of royalty	6.00%	6.00%
Birmingham Associates Ltd | AGGRASTAT | Above 400000
Commitments And Contingencies [Line Items]
Percentage of royalty	8.00%	8.00%

Related party transactions (Det

Related party transactions (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of transactions between related parties [abstract]
Salaries, fees and short-term benefits	$ 769,636	$ 1,463,106	$ 839,735
Termination benefits	0	0	221,624
Share-based payments	669,371	139,189	145,398
Total	$ 1,439,007	$ 1,602,295	$ 1,206,757

Related party transactions (D_2

Related party transactions (Detail Textuals) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of transactions between related parties [line items]
Termination benefits	$ 0	$ 0	$ 221,624
Key management personnel of entity or parent
Disclosure of transactions between related parties [line items]
Transaction bonuses included in loss from discontinued operations		750,000
Amount payable for services provided recorded within accounts payable and accrued liabilities	$ 4,683	$ 1,000	$ 13,279

Related party transactions (D_3

Related party transactions (Detail Textuals 1) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Key management personnel of entity or parent
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Voting shares of Directors and key management personnel control	17.00%	16.00%
Genesys Venture Inc
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Business administration services	$ 85,000	$ 85,000	$ 85,000
Rental costs	227,733	212,000	222,500
Commercial and information technology support services	$ 46,950	$ 43,800	$ 41,975

Related party transactions (D_4

Related party transactions (Detail Textuals 2) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Research and development expense	$ 6,681,013	$ 5,148,233	$ 3,630,079
GVI clinical development solutions Inc
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Accounts payable and accrued liabilities	134,461	118,973
GVI clinical development solutions Inc | Consulting agreement
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Research and development expense	857,917	715,623	592,464
CanAm Bioresearch Inc
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Accounts payable and accrued liabilities	40,452	36,606
CanAm Bioresearch Inc | Consulting agreement
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Research and development expense	393,021	458,424	560,205
Dap Dhaduk II LLC
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Rental expenses which are recorded within loss from discontinued operations		263,493	29,869
Aktinos
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Purchases of inventory, which were included in assets		1,599,056	217,382
Omgene life sciences Pvt Ltd
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Research and development expense		26,465
4C Pharma Solutions LLC.
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Services provided which are recorded within loss from discontinued operations		5,690
Genesys Venture Inc
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Rental expenses which are recorded within loss from discontinued operations	227,733	212,000	$ 222,500
Accounts payable and accrued liabilities	$ 16,843	$ 67,704

Related party transactions (D_5

Related party transactions (Detail Textuals 3) - CAD ($)	1 Months Ended	12 Months Ended
	Jul. 18, 2016	Dec. 31, 2018	Dec. 31, 2017
A.D. Friesen Enterprises Ltd.,
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Term of agreement	5 years
Amount payable under agreement	$ 300,000
Revised amount payable under agreement	$ 315,000
Amounts payable, related party transactions			$ 125,000
JFK Enterprises Ltd
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Term of agreement		1 year
Amount payable under agreement		$ 155,000

Expenses by nature (Details)

Expenses by nature (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Personnel expenses
Salaries, fees and short-term benefits	$ 7,696,387	$ 5,903,669	$ 5,804,883
Share-based payments	1,022,176	490,769	1,340,001
Employee benefits expense	8,718,563	6,394,438	7,144,884
Amortization and derecognition	299,184	97,794	1,433,573
Research and development	6,681,013	5,148,233	3,630,079
Manufacturing	764,712	955,160	1,062,684
Inventory material costs	3,861,740	3,079,397	2,482,986
Write-down (write-up) of inventories	94,517	385,289	(108,817)
Medical affairs	1,026,465	1,108,090	1,040,755
Administration	1,504,799	1,724,584	1,526,682
Selling and logistics	8,018,787	5,395,373	5,355,876
Professional fees	740,353	801,882	559,287
Expenses by nature	$ 30,335,588	$ 23,480,554	$ 22,768,874

Financial instruments (Details)

Financial instruments (Details) - CAD ($)	Dec. 31, 2018	Dec. 31, 2017
Accounts payable and accrued liabilities
Disclosure of detailed information about financial instruments [line items]
Carrying amount	$ 14,378,215	$ 10,371,103
Fair value	14,378,215	10,371,103
Accrued transaction costs
Disclosure of detailed information about financial instruments [line items]
Carrying amount	0	22,360,730
Fair value	0	22,360,730
Current portion of royalty obligation
Disclosure of detailed information about financial instruments [line items]
Carrying amount	1,495,548	1,537,202
Fair value	1,495,548	1,537,202
Royalty obligation
Disclosure of detailed information about financial instruments [line items]
Carrying amount	2,035,010	2,911,810
Fair value	2,035,010	2,911,810
License fee payable
Disclosure of detailed information about financial instruments [line items]
Carrying amount	0	501,800
Fair value	0	501,800
Other long-term liabilities
Disclosure of detailed information about financial instruments [line items]
Carrying amount	1,200,608	1,135,007
Fair value	1,200,608	1,135,007
Cash and cash equivalents
Disclosure of detailed information about financial instruments [line items]
Carrying amount	24,139,281	5,260,480
Fair value	24,139,281	5,260,480
Short-term investments
Disclosure of detailed information about financial instruments [line items]
Carrying amount	47,747,000	0
Fair value	47,747,000	0
Accounts receivable
Disclosure of detailed information about financial instruments [line items]
Carrying amount	10,764,579	8,588,255
Fair value	10,764,579	8,588,255
Consideration receivable
Disclosure of detailed information about financial instruments [line items]
Carrying amount	0	82,678,366
Fair value	0	82,678,366
Holdback receivable
Disclosure of detailed information about financial instruments [line items]
Carrying amount	11,909,368	12,068,773
Fair value	$ 11,909,368	$ 12,068,773

Financial instruments (Details

Financial instruments (Details 1) - CAD ($)	Dec. 31, 2018	Dec. 31, 2017
Level 1 | Accounts payable and accrued liabilities
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	$ 0	$ 0
Level 1 | Current portion of royalty obligation
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Level 1 | Royalty obligation
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Level 1 | Liabilities held for sale
Disclosure of detailed information about financial instruments [line items]
Financial liabilities		0
Level 1 | License fee payable
Disclosure of detailed information about financial instruments [line items]
Financial liabilities		0
Level 1 | Other long-term liabilities
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Level 1 | Assets held for sale
Disclosure of detailed information about financial instruments [line items]
Financial assets		0
Level 1 | Holdback receivable
Disclosure of detailed information about financial instruments [line items]
Financial assets	0	0
Level 2 | Accounts payable and accrued liabilities
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Level 2 | Current portion of royalty obligation
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Level 2 | Royalty obligation
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Level 2 | Liabilities held for sale
Disclosure of detailed information about financial instruments [line items]
Financial liabilities		6,976,313
Level 2 | License fee payable
Disclosure of detailed information about financial instruments [line items]
Financial liabilities		0
Level 2 | Other long-term liabilities
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Level 2 | Assets held for sale
Disclosure of detailed information about financial instruments [line items]
Financial assets		14,052,861
Level 2 | Holdback receivable
Disclosure of detailed information about financial instruments [line items]
Financial assets	0	0
Level 3 | Accounts payable and accrued liabilities
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	545,680	877,150
Level 3 | Current portion of royalty obligation
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	1,495,548	1,537,202
Level 3 | Royalty obligation
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	2,035,010	2,911,810
Level 3 | Liabilities held for sale
Disclosure of detailed information about financial instruments [line items]
Financial liabilities		0
Level 3 | License fee payable
Disclosure of detailed information about financial instruments [line items]
Financial liabilities		501,800
Level 3 | Other long-term liabilities
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	1,200,608	1,135,007
Level 3 | Assets held for sale
Disclosure of detailed information about financial instruments [line items]
Financial assets		0
Level 3 | Holdback receivable
Disclosure of detailed information about financial instruments [line items]
Financial assets	$ 11,909,368	$ 12,068,773

Financial instruments (Detail_2

Financial instruments (Details 2)	Dec. 31, 2018CAD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017CAD ($)	Dec. 31, 2017USD ($)
Disclosure of nature and extent of risks arising from financial instruments [line items]
Accounts receivable	$ 10,764,579		$ 8,588,255
Consideration receivable			82,678,366
Holdback receivable	11,909,368		12,068,773
Accounts payable and accrued liabilities	(14,378,215)		(10,371,103)
Income taxes payable	(1,058,487)		(2,428,560)
Current portion of royalty obligation	(1,495,548)		(1,537,202)
Royalty obligation	$ (2,035,010)		(2,911,810)
License fee payable			$ (501,800)
U.S. dollar currency risk
Disclosure of nature and extent of risks arising from financial instruments [line items]
Cash		$ 17,427,653		$ 4,086,080
Short-term investments		35,000,000		0
Accounts receivable		7,725,228		6,792,664
Consideration receivable		0		65,905,433
Holdback receivable		8,729,928		9,620,385
Accounts payable and accrued liabilities		(9,902,571)		(7,174,456)
Accrued transaction costs		0		(17,824,416)
Income taxes payable		(775,903)		(1,935,879)
Current portion of royalty obligation		(1,096,282)		(1,225,350)
Royalty obligation		(1,491,724)		(2,321,092)
License fee payable		0		(400,000)
Other long-term liability		(880,082)		(904,749)
Derivative financial assets liabilities		$ 54,736,247		$ 54,618,620

Financial instruments (Detail T

Financial instruments (Detail Textuals)	12 Months Ended
	Dec. 31, 2018CAD ($)Customer	Dec. 31, 2017CAD ($)Customer	Dec. 31, 2016CAD ($)
Disclosure of detailed information about financial instruments [line items]
Fair value measurement, Discount rate	20.00%
Concentration of credit risk, Percentage Of Accounts Receivable	91.00%	96.00%
Number of customers owing greater than 10% of accounts receivable | Customer	3	3
Bad debt expenses
Other price risk
Disclosure of detailed information about financial instruments [line items]
Amount of Change in net income due to 5% appreciation or deterioration of the Canadian dollar against the U.S. dollar	$ 3,700,000	3,800,000
Interest rate risk
Disclosure of detailed information about financial instruments [line items]
Amount of Change in net income due to 1% appreciation or deterioration of the Canadian dollar against the U.S. dollar	720,000	53,000
AGGRASTAT
Disclosure of detailed information about financial instruments [line items]
Amount of Change in royalty obligation liability if the expected revenue from AGGRASTAT sales were to change by 10%	211,000
Amount of Change in royalty obligation liability if If the discount rate used in calculating the fair value of the royalty obligation of 20% were to change by 1%	22,000
Level 3 | Accounts payable and accrued liabilities
Disclosure of detailed information about financial instruments [line items]
Current portion of the license fee payable	$ 545,680	$ 877,150

Segmented information (Details)

Segmented information (Details) - CAD ($)	Dec. 31, 2018	Dec. 31, 2017
Disclosure of geographical areas [line items]
Property, plant and equipment, intangible assets and other assets	$ 2,021,263	$ 1,977,922
Canada
Disclosure of geographical areas [line items]
Property, plant and equipment, intangible assets and other assets	316,013	218,488
Barbados
Disclosure of geographical areas [line items]
Property, plant and equipment, intangible assets and other assets	1,705,250	1,756,300
United States
Disclosure of geographical areas [line items]
Property, plant and equipment, intangible assets and other assets	$ 0	$ 3,134

Segmented information (Detail T

Segmented information (Detail Textuals)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of operating segments [line items]
Percentage of total revenue	100.00%	99.00%	100.00%
AGGRASTAT | United States
Disclosure of operating segments [line items]
Percentage of total revenue	100.00%	100.00%	100.00%

Segmented information (Detail_2

Segmented information (Detail Textuals 1) - Customer	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of operating segments [line items]
Percentage of total revenue	100.00%	99.00%	100.00%
Number of customers	8	9	9
Number of remaining customers accounted for less than 1% revenue	5	5	5
Customer A
Disclosure of operating segments [line items]
Percentage of total revenue	33.00%	33.00%	36.00%
Customer B
Disclosure of operating segments [line items]
Percentage of total revenue	28.00%	30.00%	32.00%
Customer C
Disclosure of operating segments [line items]
Percentage of total revenue	33.00%	30.00%	20.00%
Customer D
Disclosure of operating segments [line items]
Percentage of total revenue	6.00%	6.00%	11.00%

Subsequent events (Detail Textu

Subsequent events (Detail Textuals) - Marketing partner agreement - Sensible Medical Innovations Inc. ("Sensible") $ in Millions	Jan. 28, 2019USD ($)
Disclosure of non-adjusting events after reporting period [line items]
Amount invested for equity stake	$ 10
Percentage of equity stake on diluted basis	7.71%